ZURICH, Feb 1(Reuters) - The following are some of the main
factors expected to affect Swiss stocks on Wednesday.
Read more
Tuesday, January 31, 2017
BRIEF-Index Pharmaceuticals enters agreement with CRO for the conduct study
* Has entered an agreement for services with global Contract
Research Organization (CRO) parexel for implementation of
conduct study
Source text for Eikon:
Read more
Research Organization (CRO) parexel for implementation of
conduct study
Source text for Eikon:
Read more
BRIEF-Sanofi and Regeneron announce first approval of Kevzara
* Sanofi and Regeneron Pharmaceuticals, Inc. today
announced that Health Canada approved Kevzara(TM)
Read more
announced that Health Canada approved Kevzara(TM)
Read more
BRIEF-Kuwait's Al Aman Investment to merge with Securities House
* Board approves to merge with Securities House
Source:(http://bit.ly/2koZVZa)
Further company coverage:
Read more
Source:(http://bit.ly/2koZVZa)
Further company coverage:
Read more
BRIEF-D.Western Therapeutics Institute to buy ophthalmic surgical adjuvant business from Healios KK
* Says the co to buy ophthalmic surgical adjuvant business,
which includes ingredient of Brilliant Blue G-250, from Healios
KK
Read more
which includes ingredient of Brilliant Blue G-250, from Healios
KK
Read more
China services sector growth picks up in Jan-offical PMI
BEIJING, Feb 1 (Reuters) - Growth in China's services sector
accelerated in January compared with the previous month, an
official survey showed on Wednesday.
Read more
accelerated in January compared with the previous month, an
official survey showed on Wednesday.
Read more
BRIEF-Hologic completes divestiture of blood screening business
* Hologic completes divestiture of blood screening business
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-European Commission approves Keytruda for first-line treatment of patients with metastatic non-small cell lung cancer
* European Commission approves Keytruda (pembrolizumab) for
first-line treatment of patients with metastatic non-small cell
lung cancer (NSCLC) whose tumors have high PD-l1 expression with
no EGFR or ALK positive tumor mutations
Read more
first-line treatment of patients with metastatic non-small cell
lung cancer (NSCLC) whose tumors have high PD-l1 expression with
no EGFR or ALK positive tumor mutations
Read more
UPDATE 4-Trump set to name conservative judge as U.S. Supreme Court pick
WASHINGTON, Jan 31 (Reuters) - President Donald Trump was
set to unveil his pick on Tuesday for a lifetime job on the U.S.
Supreme Court, likely choosing a conservative judge to try to
shape the court for years to come on issues like abortion and
gun and religious rights.
Read more
set to unveil his pick on Tuesday for a lifetime job on the U.S.
Supreme Court, likely choosing a conservative judge to try to
shape the court for years to come on issues like abortion and
gun and religious rights.
Read more
UPDATE 4-Pfizer CEO says no need to alter its drug pricing practices
NEW YORK, Jan 31 (Reuters) - Pfizer Inc Chief
Executive Ian Read said on Tuesday the company would not change
its philosophy on pricing of its medicines or when it takes
price increases, bucking a recent trend by some rivals of the
largest U.S. drugmaker.
Read more
Executive Ian Read said on Tuesday the company would not change
its philosophy on pricing of its medicines or when it takes
price increases, bucking a recent trend by some rivals of the
largest U.S. drugmaker.
Read more
BRIEF-APPLIED BIOMATH SAYS TO COLLABORATE WITH CYTOMX THERAPEUTICS
* SAYS TO COLLABORATE WITH CYTOMX THERAPEUTICS TO DEVELOP
QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF CYTOMX THERAPEUTICS'
PROBODY PLATFORM
Source text for Eikon:
Further company coverage:
Read more
QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL OF CYTOMX THERAPEUTICS'
PROBODY PLATFORM
Source text for Eikon:
Further company coverage:
Read more
Paralysed patients communicate thoughts via brain-computer interface
LONDON, Jan 31 (Reuters) - Scientists have developed a
brain-computer interface that reads the brain's blood oxygen
levels and enables communication by deciphering the thoughts of
patients who are totally paralysed and unable to talk.
Read more
brain-computer interface that reads the brain's blood oxygen
levels and enables communication by deciphering the thoughts of
patients who are totally paralysed and unable to talk.
Read more
BRIEF-Empery Asset Management LP dissolves passive stake in Delcath Systems
* Empery Asset Management LP dissolves passive stake in
Delcath Systems Inc as of Dec 30, 2016 - SEC filing
Read more
Delcath Systems Inc as of Dec 30, 2016 - SEC filing
Read more
UPDATE 1-Senate Democrats boycott, delay committee vote on Mnuchin, Price
WASHINGTON, Jan 31 (Reuters) - U.S. Senate Democrats on
Tuesday boycotted a planned committee vote on two of President
Donald Trump's Cabinet nominees, Steve Mnuchin to be Treasury
secretary and Tom Price to head the Health and Human Services
department, delaying the vote.
Read more
Tuesday boycotted a planned committee vote on two of President
Donald Trump's Cabinet nominees, Steve Mnuchin to be Treasury
secretary and Tom Price to head the Health and Human Services
department, delaying the vote.
Read more
BRIEF-Lonza launches accelerated bookbuilding
* Following the announcement on 15 December 2016
regarding the contemplated acquisition of Capsugel, Lonza
launches an accelerated bookbuilding by offering up to 5.0
million registered shares
Read more
regarding the contemplated acquisition of Capsugel, Lonza
launches an accelerated bookbuilding by offering up to 5.0
million registered shares
Read more
UPDATE 2-Trump pushes drugmakers for lower prices, more U.S. production
WASHINGTON, Jan 31 (Reuters) - U.S. President Donald Trump
on Tuesday called on the pharmaceutical industry to boost U.S.
production and lower prices, while also vowing to speed up
approval times for new medicines and appoint a new U.S. Food and
Drug Administration leader soon.
Read more
on Tuesday called on the pharmaceutical industry to boost U.S.
production and lower prices, while also vowing to speed up
approval times for new medicines and appoint a new U.S. Food and
Drug Administration leader soon.
Read more
HIGHLIGHTS-The Trump presidency on Jan 31 at 10:38 A.M. EST/1538 GMT
Jan 31 (Reuters) - Highlights of the day for U.S. President
Donald Trump's administration on Tuesday:
Read more
Donald Trump's administration on Tuesday:
Read more
BRIEF-UnitedHealthcare says $15 mln strategic partnership with Camden Coalition
* UnitedHealthcare - $15 million strategic partnership with
Camden Coalition of Healthcare Providers to develop, test and
scale new models of care
Read more
Camden Coalition of Healthcare Providers to develop, test and
scale new models of care
Read more
Failure of malaria drug 'early warning' for Africa, researchers say
LONDON, Jan 31 (Thomson Reuters Foundation) - A drug widely
used to cure malaria has failed for the first time in patients
being treated in Britain, raising questions over whether the
parasite is becoming resistant to drugs, researchers said on
Tuesday.
Read more
used to cure malaria has failed for the first time in patients
being treated in Britain, raising questions over whether the
parasite is becoming resistant to drugs, researchers said on
Tuesday.
Read more
BRIEF-Tenax Therapeutics announces top-line results from phase 3 LEVO-CTS trial in cardiac surgery
* Tenax Therapeutics announces top-line results from phase 3
levo-cts trial in cardiac surgery
Read more
levo-cts trial in cardiac surgery
Read more
BUZZ-DJI: Post-election rally on shaky ground
** DJI has so far topped within a Fibo proj zone;
Monday's sharp set back can kick-off multi-week pull back,
though still need break of 19843.94 to confirm
Read more
Monday's sharp set back can kick-off multi-week pull back,
though still need break of 19843.94 to confirm
Read more
BRIEF-Pharmstandard shareholders approve delisting from Moscow Exchange
* Says shareholders approve delisting from Moscow Exchange
Source text: http://bit.ly/2kcktS5
Read more
Source text: http://bit.ly/2kcktS5
Read more
Pfizer quarterly revenue slips 3 percent
Jan 31 (Reuters) - Pfizer Inc, which closed its $14
billion acquisition of Medivation Inc in September, reported a 3
percent fall in quarterly revenue, due to a strong dollar and
fewer selling days compared to the year-ago quarter.
Read more
billion acquisition of Medivation Inc in September, reported a 3
percent fall in quarterly revenue, due to a strong dollar and
fewer selling days compared to the year-ago quarter.
Read more
BRIEF-Sonoma Pharmaceuticals appoints Marc Umscheid as chief strategy and marketing officer
* Sonoma Pharmaceuticals appoints Marc Umscheid as chief
strategy and marketing officer
Source text for Eikon:
Further company coverage:
Read more
strategy and marketing officer
Source text for Eikon:
Further company coverage:
Read more
BRIEF-ED lowers conversion price of 12th series bonds to 3,138 won/share
* Says it lowers conversion price of 12th series bonds to
3,138 won/share from 3,665 won/share
Read more
3,138 won/share from 3,665 won/share
Read more
BRIEF-Fresenius Medical Care reaches agreement on outstanding payments
* Reached amicable agreement with U.S. Departments of
veterans affairs and justice resolving reimbursement for
services provided to veterans
Read more
veterans affairs and justice resolving reimbursement for
services provided to veterans
Read more
Monday, January 30, 2017
GE Oil and Gas CEO sees offshore activity pick up in 2018-19
FLORENCE, Italy Jan 31 (Reuters) - Activity in offshore oil
and gas fields is expected to pick up in 2018 and 2019 as
companies revive investments after several years of low energy
prices, Lorenzo Simonelli, chief executive of GE Oil and Gas
told Reuters on Tuesday.
Read more
and gas fields is expected to pick up in 2018 and 2019 as
companies revive investments after several years of low energy
prices, Lorenzo Simonelli, chief executive of GE Oil and Gas
told Reuters on Tuesday.
Read more
BRIEF-Tigenix enrolls first patient in phase Ib/IIa clinical trial of CX611 in severe sepsis
* Enrolls first patient in phase Ib/IIa clinical trial of CX611 in severe sepsis
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Coltene Holding FY 2016 net sales up at CHF 160.7 mln
* Increased its net sales by 4.0% to 160.7 million Swiss
francs ($161.52 million)(2015: 154.5 million Swiss francs) in
financial year 2016
Read more
francs ($161.52 million)(2015: 154.5 million Swiss francs) in
financial year 2016
Read more
BRIEF-Access Bio lowers conversion price of second series bonds to 5,732 won/share
* Says it lowers conversion price of second series bonds to
5,732 won/share from 6,905 won/share
Read more
5,732 won/share from 6,905 won/share
Read more
Trump to meet pharmaceutical representatives at White House on Tuesday
WASHINGTON, Jan 30 (Reuters) - U.S. President Donald Trump,
who has criticized the high prices of prescription drugs, will
meet with representatives of the pharmaceutical industry on
Tuesday at the White House, the White House said in a statement.
Read more
who has criticized the high prices of prescription drugs, will
meet with representatives of the pharmaceutical industry on
Tuesday at the White House, the White House said in a statement.
Read more
BRIEF-Access Bio receives patent
Jan 31 (Reuters) - Access Bio Inc :
* Says it receives patent about chromatographic assay system
* Says patent number is 12/241,583
Source text in Korean: https://goo.gl/kcI1y8
Further company coverage:
(Beijing Headline News)
Read more
REFILE-Sanctuary city funding cuts less of a concern than Medicaid -Fitch
SAN FRANCISCO, Jan 30 (Reuters) - President Donald Trump's
executive order last week to cut federal funding to
self-proclaimed sanctuary cities would likely not result in an
impact to cities' bond ratings, Fitch Ratings reported on
Monday.
Read more
executive order last week to cut federal funding to
self-proclaimed sanctuary cities would likely not result in an
impact to cities' bond ratings, Fitch Ratings reported on
Monday.
Read more
BRIEF-Sirtex Medical seeks trading halt; receives letter representating proceeding against co
* Received a letter from a law firm foreshadowing
commencement of a representative proceeding against company
Read more
commencement of a representative proceeding against company
Read more
BRIEF-Aeterna Zentaris completes Zoptrex(tm) pivotal Phase 3 clinical trial in advanced endometrial cancer
* Aeterna Zentaris announces completion of Zoptrex(TM)
pivotal Phase 3 clinical trial in advanced endometrial cancer;
expects to report top-line results in April 2017
Read more
pivotal Phase 3 clinical trial in advanced endometrial cancer;
expects to report top-line results in April 2017
Read more
U.S. medical students, faculty rally to try to save Obamacare
CHICAGO, Jan 30 (Reuters) - Hundreds of medical students and
faculty members gathered at Northwestern University's school of
medicine in Chicago on Monday to voice their opposition to the
dismantling of Obamacare.
Read more
faculty members gathered at Northwestern University's school of
medicine in Chicago on Monday to voice their opposition to the
dismantling of Obamacare.
Read more
UPDATE 2-Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit
NEW YORK, Jan 30 (Reuters) - Three of the biggest makers of
diabetes treatments, Sanofi SA, Novo Nordisk
and Eli Lilly & Co, were named in a proposed
class action lawsuit by a group of patients alleging
price-fixing.
Read more
diabetes treatments, Sanofi SA, Novo Nordisk
and Eli Lilly & Co, were named in a proposed
class action lawsuit by a group of patients alleging
price-fixing.
Read more
BRIEF-Mettrum Health, Canopy Growth announced that a court has issued final order approving proposed acquisition
* Mettrum Health - Co, Canopy Growth Corporation announce
that Ontario Superior Court of Justice has issued final order
approving proposed acquisition
Source text for Eikon:
Further company coverage:
Read more
that Ontario Superior Court of Justice has issued final order
approving proposed acquisition
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Takeda Pharmaceutical and Shionogi & Co to develop treatment techniques to combat Dementia- Nikkei
* Takeda Pharmaceutical and Shionogi & Co. with three other
Japanese drug companies to develop treatment techniques to
combat Dementia
Read more
Japanese drug companies to develop treatment techniques to
combat Dementia
Read more
UPDATE 2-Keysight Technologies to buy Ixia for $1.6 billion
Jan 30 (Reuters) - Keysight Technologies Inc, a
provider of software and equipment to the electronics industry,
said on Monday it would buy U.S. data technology company Ixia
for about $1.6 billion in cash in a bid to increase its
software and security portfolio.
Read more
provider of software and equipment to the electronics industry,
said on Monday it would buy U.S. data technology company Ixia
for about $1.6 billion in cash in a bid to increase its
software and security portfolio.
Read more
Ban sparks panic among refugees awaiting urgent medical care in U.S.
SAN FRANCISCO/NEW YORK, Jan 30 (Reuters) - Al Ameen, a
33-year-old Iraqi refugee with hemophilia A, a genetic disorder
that prevents proper blood clotting, has been living in Jordan
awaiting medical care in the United States for two years. His
condition is so advanced, his doctors have told him, that only a
handful of facilities in the world can treat him.
Read more
33-year-old Iraqi refugee with hemophilia A, a genetic disorder
that prevents proper blood clotting, has been living in Jordan
awaiting medical care in the United States for two years. His
condition is so advanced, his doctors have told him, that only a
handful of facilities in the world can treat him.
Read more
Luxottica's retail push lifts 2016 sales 1 pct
MILAN, Jan 30 (Reuters) - Italian eyewear group Luxottica
reported on Monday a 0.8 percent rise in 2016 adjusted
sales helped by its fast-expanding retail network, while
reorganisation efforts in the U.S. and Chinese markets hit its
wholesale business.
Read more
reported on Monday a 0.8 percent rise in 2016 adjusted
sales helped by its fast-expanding retail network, while
reorganisation efforts in the U.S. and Chinese markets hit its
wholesale business.
Read more
BRIEF-BioDue obtains two loans for total EUR 2.6 mln
* Obtains two medium/long term loans in the amount of total 2.6 million euros ($2.78
million)
Source text: www.1info.it
Further company coverage:
($1 = 0.9356 euros)
(Gdynia Newsroom)
Read more
million)
Source text: www.1info.it
Further company coverage:
($1 = 0.9356 euros)
(Gdynia Newsroom)
Read more
BRIEF-Biofrontera: European Commission extends Ameluz approval to basal cell carcinoma
* European Commission extends Ameluz approval to basal cell carcinoma
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Activist investor Voce threatens proxy war at Air Methods
Jan 30 (Reuters) - Activist hedge fund Voce Capital
Management LLC on Monday threatened it would start a proxy war
at Air Methods Corp, saying the U.S. medical helicopter
company needed an urgent change of directors and strategy.
Read more
Management LLC on Monday threatened it would start a proxy war
at Air Methods Corp, saying the U.S. medical helicopter
company needed an urgent change of directors and strategy.
Read more
UPDATE 2-Walgreens delays Rite Aid deal again, cuts offer price
Jan 30 (Reuters) - Drugstore chain Walgreens Boots Alliance
Inc said its deal to buy smaller rival Rite Aid Corp
would now take six months longer to close and reduced
its offer price, as it expects to divest more stores to gain
regulatory approval.
Read more
Inc said its deal to buy smaller rival Rite Aid Corp
would now take six months longer to close and reduced
its offer price, as it expects to divest more stores to gain
regulatory approval.
Read more
BRIEF-Cannimed Therapeutics says raised about $5.15 mln in equity financing
* Cannimed Therapeutics Inc says it has raised $5.15 million
in equity financing from total offering amount of $5.15 million
- sec filing
Source text : http://bit.ly/2jNCBAJ
Further company coverage:
Read more
in equity financing from total offering amount of $5.15 million
- sec filing
Source text : http://bit.ly/2jNCBAJ
Further company coverage:
Read more
Osram says gets German government approval for Lamps sale
FRANKFURT, Jan 30 (Reuters) - Lighting group Osram
has received approval from the German government for the 400
million euro ($425 million) sale of its Lamps unit to a
consortium of Chinese bidders, a spokesman said on Monday.
Read more
has received approval from the German government for the 400
million euro ($425 million) sale of its Lamps unit to a
consortium of Chinese bidders, a spokesman said on Monday.
Read more
UPDATE 1-Trump travel ban stirs faint corporate outcry beyond Silicon Valley
(Adds comments from Goldman Sachs' chief executive)
By Devika Krishna Kumar and Ross Kerber
NEW YORK/BOSTON, Jan 30 (Reuters) - Most U.S. corporate
bosses have stayed silent on President Donald Trump's
immigration curbs, underscoring the sensitivities around
opposing policies that could provoke a backlash from the White
House.
While the leaders of Apple Inc, Google
and Facebook Inc emailed their staff to denounce the
suspension of the U.S. refugee program and the halting of
arri
Read more
BRIEF-Syncom Healthcare says approved appointment of Ajay Shankarlal Bankda as MD
* Says approved appointment of Ajay Shankarlal Bankda as MD
Source text: (http://bit.ly/2kFzL1j)
Further company coverage:
Read more
Source text: (http://bit.ly/2kFzL1j)
Further company coverage:
Read more
BRIEF-Incyte and Calithera Biosciences announce global collaboration to develop and commercialize CB-1158
* Incyte and calithera biosciences announce global
collaboration to develop and commercialize CB-1158, a
first-in-class, small molecule arginase inhibitor
Read more
collaboration to develop and commercialize CB-1158, a
first-in-class, small molecule arginase inhibitor
Read more
UPDATE 1-Danish drugmaker Novo Nordisk bets $145 mln on post-Brexit UK science
* Government welcomes "vote of confidence" in UK
(Adds comment from minister and Novo chief science officer)
Read more
(Adds comment from minister and Novo chief science officer)
Read more
BRIEF-GreenPeptide announces exercise of options
* Says 1,380 units of its 9th series options were exercised
to 1.38 million shares of its common stock in January
Read more
to 1.38 million shares of its common stock in January
Read more
BRIEF-Piramal Enterprises unit buys portfolio of drugs from Mallinckrodt LLC
* Says Piramal Enterprises announces acquisition of a
portfolio of drugs for spasticity and pain management from
Mallinckrodt Llc
Read more
portfolio of drugs for spasticity and pain management from
Mallinckrodt Llc
Read more
Sunday, January 29, 2017
BRIEF-Solon Eiendom: Proceeds from subsequent offering NOK 100 million
* Preliminary counting of subscriptions in subsequent offering indicates that about 116
million shares have been subscribed for out of total of 666,666,666 shares available
Read more
million shares have been subscribed for out of total of 666,666,666 shares available
Read more
German stocks - Factors to watch on January 30
FRANKFURT/BERLIN, Jan 30 (Reuters) - The following are some
of the factors that may move German stocks on Monday:
Read more
of the factors that may move German stocks on Monday:
Read more
BRIEF-Suven Life Sciences secures product patent in U.S.
* Says Suven Life Sciences secures a product patent in USA
Source text: http://bit.ly/2jtMu5r
Further company coverage:
Read more
Source text: http://bit.ly/2jtMu5r
Further company coverage:
Read more
BRIEF-Medibio says negotiated early repayment of convertible note
* Has negotiated early repayment of a us$2.5 million
convertible note
Source text for Eikon:
Further company coverage:
Read more
convertible note
Source text for Eikon:
Further company coverage:
Read more
Back to zero: Companies use 1970s budget tool to cut costs as they hunt for growth
BOSTON, Jan 30 (Reuters) - The number of U.S. companies
using a budgeting tool made famous in the 1970s by former U.S.
President Jimmy Carter is surging as they turn their spending
habits upside down to boost profits and to re-invest in their
businesses.
Read more
using a budgeting tool made famous in the 1970s by former U.S.
President Jimmy Carter is surging as they turn their spending
habits upside down to boost profits and to re-invest in their
businesses.
Read more
Trump travel ban stirs faint corporate outcry beyond Silicon Valley
By Devika Krishna Kumar and Ross Kerber
NEW YORK/BOSTON, Jan 30 (Reuters) - Most U.S. corporate
bosses have stayed silent on President Donald Trump's
immigration curbs, underscoring the sensitivities around
opposing policies that could provoke a backlash from the White
House.
While the leaders of Apple Inc, Google
and Facebook Inc emailed their staff to denounce the
suspension of the U.S. refugee program and the halting of
arrivals from seven Muslim-majority countries, many of their
co
Read more
NEW YORK/BOSTON, Jan 30 (Reuters) - Most U.S. corporate
bosses have stayed silent on President Donald Trump's
immigration curbs, underscoring the sensitivities around
opposing policies that could provoke a backlash from the White
House.
While the leaders of Apple Inc, Google
and Facebook Inc emailed their staff to denounce the
suspension of the U.S. refugee program and the halting of
arrivals from seven Muslim-majority countries, many of their
co
Read more
BRIEF-Astellas and Ironwood report positive top-line results from phase III Linaclotide trial in Japan
* Astellas and Ironwood report positive top-line results
from phase III Linaclotide trial for patients with chronic
constipation conducted in Japan
Read more
from phase III Linaclotide trial for patients with chronic
constipation conducted in Japan
Read more
BRIEF-Dentas to sell entire 100 pct stake in Hokkaido dental tech firm
* Says the co plans to entire 100 percent stake in
Hokkaido-based dental tech firm on Jan. 31
Read more
Hokkaido-based dental tech firm on Jan. 31
Read more
BRIEF-Neuren Pharmaceuticals completes Phase 2 trial in Pediatric Rett Syndrome
* Neuren completes phase 2 trial in Pediatric Rett Syndrome
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Benitec Biopharma initiates work on two oncology pipeline programs
* Initiated work on two new oncology pipeline programs after
executing a research collaboration agreement with Nant Capital
Llc
Source text for Eikon:
Further company coverage:
Read more
executing a research collaboration agreement with Nant Capital
Llc
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Total Face Group expects HY EBITDA excluding one-offs of approximately $1.0 mln
* "Expect revenue for half to reach $10.0m and we expect to
maintain gross margins above 70% and clinic profitability above
25%"
Read more
maintain gross margins above 70% and clinic profitability above
25%"
Read more
Dutch commit $10 million to replace lost U.S. abortion funding
AMSTERDAM, Jan 28 (Reuters) - The Netherlands has committed
$10 million for an initiative to replace funding for abortion
services in developing countries that will be lost due to U.S.
President Donald Trump's ban on financing foreign groups that
provide abortions.
Read more
$10 million for an initiative to replace funding for abortion
services in developing countries that will be lost due to U.S.
President Donald Trump's ban on financing foreign groups that
provide abortions.
Read more
Saturday, January 28, 2017
RPT-Trump aides divided over policy shielding 'dreamer' immigrants -sources
WASHINGTON, Jan 28 (Reuters) - Divisions have emerged among
advisers to President Donald Trump over whether to rescind a
signature policy of his predecessor, President Barack Obama,
that shields young immigrants from deportation, according to
congressional sources and Republicans close to the White House.
Read more
advisers to President Donald Trump over whether to rescind a
signature policy of his predecessor, President Barack Obama,
that shields young immigrants from deportation, according to
congressional sources and Republicans close to the White House.
Read more
Europe faces steep price increases for some old cancer drugs
LONDON, Jan 28 (Reuters) - European prices for some
off-patent cancer drugs have risen by more than 100 percent in
the past five years, with two cases of hikes exceeding 1,000
percent, according to data presented at a medical conference on
Saturday.
Read more
off-patent cancer drugs have risen by more than 100 percent in
the past five years, with two cases of hikes exceeding 1,000
percent, according to data presented at a medical conference on
Saturday.
Read more
Trump aides divided over policy shielding 'dreamer' immigrants -sources
WASHINGTON, Jan 28 (Reuters) - Divisions have emerged among
advisers to President Donald Trump over whether to rescind a
signature policy of his predecessor, President Barack Obama,
that shields young immigrants from deportation, according to
congressional sources and Republicans close to the White House.
Read more
advisers to President Donald Trump over whether to rescind a
signature policy of his predecessor, President Barack Obama,
that shields young immigrants from deportation, according to
congressional sources and Republicans close to the White House.
Read more
UPDATE 1-FDA warns against use of homeopathic teething products
Jan 27 (Reuters) - The U.S. Food and Drug Administration on
Friday warned consumers against using certain homeopathic
teething products, saying it has found high amounts of a toxic
substance in some of them and they pose a potential risk to
infants and children.
Read more
Friday warned consumers against using certain homeopathic
teething products, saying it has found high amounts of a toxic
substance in some of them and they pose a potential risk to
infants and children.
Read more
UPDATE 2-U.S. judge blocks Texas regulations for fetal tissue remains
AUSTIN, Texas, Jan 27 (Reuters) - A federal judge in Texas
on Friday halted state regulations that would require abortion
providers to dispose of aborted fetal tissue through burial or
cremation, saying the rules imposed "undue burdens on a woman's
right to seek a previability abortion."
Read more
on Friday halted state regulations that would require abortion
providers to dispose of aborted fetal tissue through burial or
cremation, saying the rules imposed "undue burdens on a woman's
right to seek a previability abortion."
Read more
UPDATE 3-Tycoon Slim says Trump not 'Terminator,' sees opportunities for Mexico
MEXICO CITY, Jan 27 (Reuters) - Billionaire Carlos Slim said
on Friday that Mexico should not fear Donald Trump, seeing
opportunities for his country in the U.S. president's economic
policies, and praising Mexicans for uniting behind their
government in talks with the northern neighbor.
Read more
on Friday that Mexico should not fear Donald Trump, seeing
opportunities for his country in the U.S. president's economic
policies, and praising Mexicans for uniting behind their
government in talks with the northern neighbor.
Read more
Friday, January 27, 2017
Merck reveals 7 years of its U.S. drug price increase history
Jan 27 (Reuters) - Merck & Co on Friday posted seven
years of information showing a high single-digit percentage
annual average price hike across its portfolio of medicines in a
move that provides new details on its pricing practices for the
U.S. market.
Read more
years of information showing a high single-digit percentage
annual average price hike across its portfolio of medicines in a
move that provides new details on its pricing practices for the
U.S. market.
Read more
(EN) SteamBroker
What is "SteamBroker"?
SteamBroker service provides marketplace to trade items from digital distribution platform Steam™. Using our marketplace you can buy goods from other users or sell any items from your inventory yourself, which can be exchanged with Steam™ trade offers. For example, items from such games as Dota 2™, Counter Strike: Global Offensive™ (CS:GO), Team Fortress™, Unturned™ and so on. Also it's possible to buy and sell Steam Trading Cards and any games, presented as a Steam gifts if you already can exchange it. You will pay a price set by other users for it, so will guarantee you lowest possible prices. You can even get discounts in case of constant use of our service.
SteamBroker guarantees the absolute security for all deals. All items will be exchanged through our service Steam accounts, these accounts will be your automatic MiddleMan and will guarantee an accuracy of transferring the items to the buyer and money paid to seller.
Go to SteamBroker
SteamBroker
Что такое "SteamBroker"?
Сервис SteamBroker предоставляет площадку для торговли вещами из сервиса цифровой дистрибуции Steam. На нашей площадке вы можете купить у других пользователей или продать сами любые предметы из Вашего инвентаря, которые возможно передать через торговое предложение Steam. Например, вещи из таких игр как Dota™ 2, Counter Strike: Global Offensive™ (CS:GO), Team Fortress™ 2, H1Z1 и прочих. А так же возможна продажа коллекционных карточек Steam и даже игр, в виде подарков в инвентаре, которые так же возможно передавать. Вы можете купить вещи за ту цену, которую указывают другие пользователи, что гарантирует отличные цены без лишних наценок.
Так же Вы можете использовать наш сайт как магазин для своих предметов. Вы получите персональную ссылку которая будет отображать только Ваши предметы.
Наш сервис гарантирует абсолютную безопасность всех сделок. Товары передаются через наши сервисные аккаунты Steam, которые выступают в качестве гаранта и контролируют точность получения вещей покупателем и выплату денег продавцу.
Перейти на SteamBroker
(EN) Steam-Trader
Steam-trader.com - Trade platform Dota2, CS:GO, TF2, Gifts.
It is a unique traiding platform, allowing you to buy and sell cosmetic items of Dota 2, CS:GO, Team Fortress2 or Games (Gifts) for real money, at the best prices! Trading platform consists of four sections, which are interlinked by a shared wallet that will allow you to sell things in one section and buy them in another. Deposit and withdrawal funds available with the help of multiple payment systems. Earn - resting! Successful auction!
Go to Steam-trader
Steam-Trader
Steam-trader - Торговая площадка Dota2, CS:GO, TF2, Gifts.
Это уникальная торговая площадка, позволяющая покупать и продавать Игры или Гифты (Gift) Steam, а так же вещи Dota 2, CS:GO, Team Fortress2 за реальные деньги, без комиссии! Торговая площадка состоит из четырех разделов, которые связанны между собой общим кошельком, что позволит вам продавать вещи в одном разделе и покупать их в другом. Пополнение счета и вывод средств доступно при помощи множества платежных систем.
Выводи деньги из Steam! Зарабатывай - отдыхая!
Перейти на Steam-trader
BRIEF-Canopy Growth and Mettrum announce respective shareholder approvals of the plan of arrangement
* Canopy Growth and Mettrum announce respective shareholder
approvals of the plan of arrangement
Read more
approvals of the plan of arrangement
Read more
Trump says he had 'very good' call with Mexico's Pena Nieto
WASHINGTON, Jan 27 (Reuters) - U.S. President Donald Trump
said he had a "very good" phone call with Mexican President
Enrique Pena Nieto on Friday and agreed to work to improve ties
after a meeting between the two leaders was scrapped amid a
dispute over funding Trump's planned border wall.
Read more
said he had a "very good" phone call with Mexican President
Enrique Pena Nieto on Friday and agreed to work to improve ties
after a meeting between the two leaders was scrapped amid a
dispute over funding Trump's planned border wall.
Read more
BRIEF-AbbVie says continues to see good Humira growth in international markets despite indirect biosimilar competition - Conf Call
* AbbVie says continues to see good Humira growth in
international markets despite indirect biosimilar competition:
Conf Call
Read more
international markets despite indirect biosimilar competition:
Conf Call
Read more
BRIEF-Human Health Holdings expects a decrease in HY profit
* Profit attributable to shareholders for six months ended
31 December 2016 is expected to decrease by approximately HK$3
million
Read more
31 December 2016 is expected to decrease by approximately HK$3
million
Read more
UPDATE 1-Drugmaker AbbVie's quarterly revenue misses estimates
Jan 27 (Reuters) - AbbVie Inc's quarterly adjusted
revenue missed analysts' estimate, in part due to
lower-than-expected sales of its hepatitis C drug and cancer
treatment.
Read more
revenue missed analysts' estimate, in part due to
lower-than-expected sales of its hepatitis C drug and cancer
treatment.
Read more
BRIEF-Juno Therapeutics appoints Corsee Sanders as head of development operations
* Juno Therapeutics appoints Corsee D. Sanders as executive
vice president and head of development operations
Source text for Eikon:
Further company coverage:
Read more
vice president and head of development operations
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Select Medical Holdings Corp announces estimate of fourth quarter results
* Select Medical Holdings Corporation announces estimate of
results for fourth quarter and year ended December 31, 2016 in
connection with refinancing discussions
Read more
results for fourth quarter and year ended December 31, 2016 in
connection with refinancing discussions
Read more
RPT-Republican ideas for healthcare reforms could spell trouble for U.S. states
SAN FRANCISCO/NEW YORK, Jan 27 (Reuters) - President Donald
Trump's push to fulfill a campaign promise to replace Obamacare,
his predecessor's signature healthcare plan, with the help of a
Republican-controlled Congress, could add to U.S. states'
financial strain.
Read more
Trump's push to fulfill a campaign promise to replace Obamacare,
his predecessor's signature healthcare plan, with the help of a
Republican-controlled Congress, could add to U.S. states'
financial strain.
Read more
BRIEF-Emergent BioSolutions receives German Federal Ministry of Health Approval of Building 55 for large-scale manufacturing of BioThrax
* Emergent BioSolutions receives German Federal Ministry of
Health Approval of Building 55 for large-scale manufacturing of
BioThrax
Read more
Health Approval of Building 55 for large-scale manufacturing of
BioThrax
Read more
BRIEF-Vicore pharma receives orphan drug designation from FDA for treatment of IPF
* Has been granted orphan drug designation from FDA for
treatment of IPF
Source text for Eikon:
Read more
treatment of IPF
Source text for Eikon:
Read more
Roche cancer drug taking bite out of Bristol's Opdivo
ZURICH, Jan 27 (Reuters) - Roche's cancer drug
Tecentriq hit the market months behind immuno-oncology (I/O)
medicines from Merck and Bristol-Myers Squibb Co
but the Swiss drugmaker's treatment is making up lost ground.
Read more
Tecentriq hit the market months behind immuno-oncology (I/O)
medicines from Merck and Bristol-Myers Squibb Co
but the Swiss drugmaker's treatment is making up lost ground.
Read more
BRIEF-Aarey Drugs & Pharma seeks members' nod for preferential allotment of 1.5 mln shares
* Seeks members' nod for preferential allotment of 1.5
million shares to non promoters at 52 rupees per share
Source text: http://bit.ly/2jb3xy0
Further company coverage:
Read more
million shares to non promoters at 52 rupees per share
Source text: http://bit.ly/2jb3xy0
Further company coverage:
Read more
BRIEF-Dr.Reddy's Labs says co not served with legal papers in matter as in Mezzion's press release
* Dr.Reddy's Laboratories clarifies on news item "Korean
biotech firm Mezzion Pharma files suit against Dr Reddy's
laboratories."
Read more
biotech firm Mezzion Pharma files suit against Dr Reddy's
laboratories."
Read more
BRIEF-Anhui Anke Biotechnology (Group) sees FY 2016 net profit up 11 pct to 25 pct
* Sees FY 2016 net profit to increase by 11 percent to 25
percent, or to be 26 million yuan to 29.3 million yuan
Read more
percent, or to be 26 million yuan to 29.3 million yuan
Read more
BRIEF-ShanXi C&Y Pharmaceutical Group expects FY 2016 net profit to increase by 10 to 35 pct
* Says net profit of FY 2016 expected to increase by 10
percent to 35 percent, or to be 25.2 million to 30.9 million
yuan
Read more
percent to 35 percent, or to be 25.2 million to 30.9 million
yuan
Read more
Thursday, January 26, 2017
BRIEF-PCI Biotech gets NOK 13.8 mln to further development of PCI for use in vaccination
* PCI Biotech awarded 13.8 million Norwegian crowns ($1.7 million) from Research Council of
Norway to further development of PCI for use in vaccination
Read more
Norway to further development of PCI for use in vaccination
Read more
BRIEF-Stallergenes Greer announces positive results of phase 3 study for allergic rhinitis
* Stallergenes Greer announces positive top-line results of phase 3 study for pediatric
house dust mite-induced allergic rhinitis
Read more
house dust mite-induced allergic rhinitis
Read more
German stocks - Factors to watch on January 27
BERLIN/FRANKFURT, Jan 27 (Reuters) - The following are some
of the factors that may move German stocks on Friday:
Read more
of the factors that may move German stocks on Friday:
Read more
Teva's Barr Labs settles Cipro antitrust case for $225 mln
Jan 26 (Reuters) - Teva Pharmaceutical Industries Ltd's
Barr Laboratories Inc has reached a $225 million
settlement in an antitrust class action that accused the
drugmaker of keeping a generic version of Bayer AG's
antibiotic Cipro off the market, court documents showed.
Read more
Barr Laboratories Inc has reached a $225 million
settlement in an antitrust class action that accused the
drugmaker of keeping a generic version of Bayer AG's
antibiotic Cipro off the market, court documents showed.
Read more
BRIEF-Jounce Therapeutics announces pricing of initial public offering
* says pricing of its initial public offering of 6.3 million
shares of common stock at a public offering price of $16.00 per
share
Read more
shares of common stock at a public offering price of $16.00 per
share
Read more
F&P Healthcare considers Mexico production changes if Trump raises tariffs
WELLINGTON, Jan 27 (Reuters) - New Zealand medical device
firm Fisher & Paykel Healthcare will consider switching
making products bound for the United States from Tijuana to New
Zealand if U.S. President Donald Trump's administration taxes
Mexican imports.
Read more
firm Fisher & Paykel Healthcare will consider switching
making products bound for the United States from Tijuana to New
Zealand if U.S. President Donald Trump's administration taxes
Mexican imports.
Read more
UPDATE 1-U.S. fund investors seek safety after Trump rally in latest week
(Adds details on mutual funds and ETFs, analyst comment, table)
By Trevor Hunnicutt
NEW YORK, Jan 26 (Reuters) - Investors pulled cash from
stock funds and bought government bonds during the latest week,
favoring a defensive stance over the risk-trading spectacle that
has followed the presidential election, Lipper data for
U.S.-based funds showed on Thursday.
U.S.-based stock mutual funds and exchange-traded funds
posted $5.7 billion in outflows during the week through Jan. 25,
wh
Read more
BRIEF-International Healthway clarifies on matter involving Lim Beng Choo
* Clarify co reported matter involving Lim Beng Choo leaving
office premises with her computer and some documents to police
Read more
office premises with her computer and some documents to police
Read more
Investors pull $5.7 bln from U.S. stock funds in latest week -Lipper
NEW YORK, Jan 26 (Reuters) - Investors pulled $5.7 billion
from U.S.-based stock funds during the week through Jan. 25,
unraveling a move into equities following the presidential
election last year Lipper data showed on Thursday.
Read more
from U.S.-based stock funds during the week through Jan. 25,
unraveling a move into equities following the presidential
election last year Lipper data showed on Thursday.
Read more
House lawmaker seeks more documents in FDA criminal office inquiry
WASHINGTON, Jan 26 (Reuters) - A top U.S. lawmaker accused
the Food and Drug Administration on Friday of failing to hand
over documents that would show whether its criminal office is
fulfilling the critical mission of protecting public health.
Read more
the Food and Drug Administration on Friday of failing to hand
over documents that would show whether its criminal office is
fulfilling the critical mission of protecting public health.
Read more
BRIEF-K2m Group announces proposed share sale by selling stockholders
* K2m Group Holdings Inc announces proposed sale of shares
of common stock by selling stockholders
Read more
of common stock by selling stockholders
Read more
BRIEF-OpGen sees 24 pct fall in Q4 revenue
* Total revenue for Q4 of 2016 is expected to be
approximately $1.0 million, a decrease of approximately 24%
Read more
approximately $1.0 million, a decrease of approximately 24%
Read more
BRIEF-Yield10 Bioscience reports preliminary 2016 Camelina field test results
* Yield10 bioscience reports preliminary 2016 camelina field
test results showing that the c3003 trait produces significant
improvements in seed yield
Source text for Eikon:
Further company coverage:
Read more
test results showing that the c3003 trait produces significant
improvements in seed yield
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Celldex Therapeutics files for offering of up to 18.4 mln shares of common stock
* Files for offering of up to 18.4 million shares of common
stock by the selling stockholders
Source text : (http://bit.ly/2kpoaTY)
Further company coverage:
Read more
stock by the selling stockholders
Source text : (http://bit.ly/2kpoaTY)
Further company coverage:
Read more
BRIEF-Abano Healthcare Group Limited continues to oppose offer from Healthcare Partners
* Board of Abano continues to recommend that shareholders
reject partial takeover offer from Healthcare Partners
Source text for Eikon:
Further company coverage:
Read more
reject partial takeover offer from Healthcare Partners
Source text for Eikon:
Further company coverage:
Read more
UPDATE 1-Trump, Republican lawmakers wrestle over priorities for 'bold' agenda
PHILADELPHIA, Jan 26 (Reuters) - President Donald Trump
pushed Republican lawmakers on Thursday for swift action on his
agenda including funding a U.S.-Mexican border wall, rewriting
the tax code and repealing the Obamacare law, despite tensions
over timetables and priorities.
Read more
pushed Republican lawmakers on Thursday for swift action on his
agenda including funding a U.S.-Mexican border wall, rewriting
the tax code and repealing the Obamacare law, despite tensions
over timetables and priorities.
Read more
BRIEF-Theradiag receives support for its development of microRNA biomarkers in oncology from Eurostars-Eureka Program
* Receives support for its development of microRNA biomarkers in oncology from the
Eurostars-Eureka Program
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
Eurostars-Eureka Program
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
UPDATE 1-Bristol-Myers cuts 2017 outlook amid Opdivo competition
Jan 26 (Reuters) - Bristol-Myers Squibb Co on
Thursday posted fourth-quarter profits that fell short of Wall
Street estimates and lowered its 2017 earnings forecast amid
tempered expectations for its key Opdivo immuno-oncology drug.
Read more
Thursday posted fourth-quarter profits that fell short of Wall
Street estimates and lowered its 2017 earnings forecast amid
tempered expectations for its key Opdivo immuno-oncology drug.
Read more
Federal judge rejects Ohio's new lethal injection process, stays executions
CLEVELAND, Jan 26 (Reuters) - A federal judge dismissed
Ohio's new three-drug lethal injection process on Thursday,
declaring it unconstitutional and problematic, and extended the
delay of three upcoming executions, according to court
officials.
Read more
Ohio's new three-drug lethal injection process on Thursday,
declaring it unconstitutional and problematic, and extended the
delay of three upcoming executions, according to court
officials.
Read more
BRIEF-Hemispherx Biopharma says order of newly manufactured Rintatolimod has been shipped
* Hemispherx Biopharma Inc says order of newly manufactured
Rintatolimod for sale utilizing early access program in Europe
has been shipped
Source text for Eikon:
Further company coverage:
Read more
Rintatolimod for sale utilizing early access program in Europe
has been shipped
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Celgene CEO says tax reform could provide significant benefit to U.S. economy, healthcare industry - Conf Call
* Celgene says Q4 topline growth was predominantly volume
driven with 14 percent of growth coming from product volume:
Conf Call
Read more
driven with 14 percent of growth coming from product volume:
Conf Call
Read more
BRIEF-Beijing Leadman Biochemistry sees FY 2016 net profit down 50 pct to 70 pct
* Sees FY 2016 net profit to decrease by 50 percent to 70
percent, or to be 47.2 million yuan to 78.6 million yuan
Read more
percent, or to be 47.2 million yuan to 78.6 million yuan
Read more
BRIEF-Medtronic to cover leadless cardiac pacemakers for use in the U.S.
* Medtronic announces medicare coverage decision for the
first and only leadless pacemaker available for use in the U.S.
Read more
first and only leadless pacemaker available for use in the U.S.
Read more
BRIEF-Qiagen announces adjustment of conversion ratio under its 0.375pct senior unsecured convertible notes
* Qiagen announces adjustment of conversion ratio under its
0.375 pct senior unsecured convertible notes due 2019 (isin
xs1046477235)
Read more
0.375 pct senior unsecured convertible notes due 2019 (isin
xs1046477235)
Read more
BRIEF-Auris Medical resumes enrollment in tactt3 phase 3 trial of Keyzilen
* Auris Medical resumes enrollment in tactt3 phase 3 trial
of keyzilen in acute and post-acute tinnitus
Read more
of keyzilen in acute and post-acute tinnitus
Read more
BRIEF-Exemplar Genetics awarded subcontract to advance new therapeutic models for sickle cell disease
* Exemplar genetics awarded subcontract to advance new
therapeutic models for sickle cell disease
Read more
therapeutic models for sickle cell disease
Read more
BRIEF-Abiomed Q3 earnings per share $0.34
* Says increasing lower end of its fiscal year 2017 revenue
guidance with new range of $440 million to $445 million
Read more
guidance with new range of $440 million to $445 million
Read more
BRIEF-Medtronic receives IDE approval to initiate study of in.pact admiral drug-coated balloon
* Medtronic receives IDE approval to initiate study of
in.pact admiral drug-coated balloon for a new indication in
patients with end-stage renal disease
Source text for Eikon:
Further company coverage:
Read more
in.pact admiral drug-coated balloon for a new indication in
patients with end-stage renal disease
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Quest Diagnostics Partners with Montefiore Health System to deliver high-value, innovative laboratory services
* Quest Diagnostics Partners with Montefiore Health System
to deliver high-value, innovative laboratory services
Read more
to deliver high-value, innovative laboratory services
Read more
BRIEF-Jupiter says J&J purchase of Actelion "very good outcome"
Jan 26 (Reuters) - * Jupiter Fund Manager Mike
Buhl-nielsen: Johnson & Johnson purchase of actelion
is "very good outcome", says can see "clear synergies
for j&j"
Read more
Buhl-nielsen: Johnson & Johnson purchase of actelion
is "very good outcome", says can see "clear synergies
for j&j"
Read more
BRIEF-AstraZeneca says asthma drug granted paediatric exclusivity in U.S.
* Says decision was based on evaluation of trials conducted
in children with asthma aged six up to 12 years in response to a
written request
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom)
Read more
in children with asthma aged six up to 12 years in response to a
written request
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom)
Read more
UPDATE 4-Johnson & Johnson to buy Actelion for $30 bln, spin off R&D unit
* J&J says deal immediately accretive to adjusted EPS
(Adds fund manager, analyst, updates shares)
Read more
(Adds fund manager, analyst, updates shares)
Read more
Actelion top-40 investor calls J&J buyout "very attractive"
ZURICH, Jan 26 (Reuters) - Johnson & Johnson's $30
billion offer to buy Swiss biotech Actelion including a
plan to spin out a separate research company is "very
attractive", one of Actelion's 40 biggest investors said on
Thursday.
Read more
billion offer to buy Swiss biotech Actelion including a
plan to spin out a separate research company is "very
attractive", one of Actelion's 40 biggest investors said on
Thursday.
Read more
UPDATE 2-Singapore factory output records strongest rise in 5 years
SINGAPORE, Jan 26 (Reuters) - Singapore's industrial
production in December grew at the strongest pace in five years
as electronics output surged, raising the chances of an upward
revision to fourth-quarter growth.
Read more
production in December grew at the strongest pace in five years
as electronics output surged, raising the chances of an upward
revision to fourth-quarter growth.
Read more
BRIEF-Sinocare says 2016 div payment
* Says it to pay a cash dividend of 3.6 yuan (before tax)
for every 10 shares and to use additional paid-in capital to
distribute 2 new shares for every 10 shares to shareholders as
2016 dividend
Read more
for every 10 shares and to use additional paid-in capital to
distribute 2 new shares for every 10 shares to shareholders as
2016 dividend
Read more
U.S. court issues injunction on assistance for dialysis patients
FRANKFURT, Jan 26 (Reuters) - A U.S. court has issued a
preliminary injunction on a new federal rule that dialysis
providers have said would prevent patients from using charitable
assistance to buy private health insurance, Fresenius Medical
Care (FMC) said on Thursday.
Read more
preliminary injunction on a new federal rule that dialysis
providers have said would prevent patients from using charitable
assistance to buy private health insurance, Fresenius Medical
Care (FMC) said on Thursday.
Read more
Wednesday, January 25, 2017
UPDATE 1-Johnson & Johnson to buy Actelion for $30 bln
ZURICH, Jan 26 (Reuters) - Swiss biotech company Actelion
said on Thursday it had agreed to be purchased by
Johnson & Johnson in a $30 billion all-cash deal,
following weeks of speculation a deal was imminent.
Read more
said on Thursday it had agreed to be purchased by
Johnson & Johnson in a $30 billion all-cash deal,
following weeks of speculation a deal was imminent.
Read more
BRIEF-Orexo swings to net profit in Q4
* Q4 net earnings msek 33.3 (-51.8)
Source text for Eikon:
Further company coverage:
(Stockholm Newsroom)
Read more
Source text for Eikon:
Further company coverage:
(Stockholm Newsroom)
Read more
BRIEF-Santhera Pharmaceuticals: CHF 49.8 mln in cash and cash equivalents by end of 2016
* Reports FY net revenues of 19.0 million Swiss francs
($19.02 million)(+340% year-on-year) from sales of its lead
product Raxone for treatment of leber's hereditary optic
neuropathy (LHON)
Read more
($19.02 million)(+340% year-on-year) from sales of its lead
product Raxone for treatment of leber's hereditary optic
neuropathy (LHON)
Read more
BRIEF-Novartis says Alcon launches new lens for astigmatism
* Says Alcon launches new trifocal toric intraocular lens
for patients with astigmatism undergoing cataract surgery
Further company coverage:
(Reporting By Zurich newsroom)
Read more
for patients with astigmatism undergoing cataract surgery
Further company coverage:
(Reporting By Zurich newsroom)
Read more
BRIEF-Jiangsu Sihuan Bioengineering completes stake exchange for investment firm
* Says co completes using 12 percent stake in co's wholly
owned bio-pharma unit in exchange for 100 percent stake in a
Guangxi-based investment firm
Read more
owned bio-pharma unit in exchange for 100 percent stake in a
Guangxi-based investment firm
Read more
BRIEF-Huons receives patent
* Says it received patent on Jan. 25, for method for
manufacturing high purity free form-astaxanthin
Read more
manufacturing high purity free form-astaxanthin
Read more
BRIEF-Sichuan Maccura Biotechnology plans cooperation with Hitachi High-Tech Diagnostics (Shanghai) Ltd
* Says the company enters into strategic cooperation
agreement with Hitachi High-Tech Diagnostics (Shanghai) Ltd
(HTD), on sale and marketing of HTD's products
Read more
agreement with Hitachi High-Tech Diagnostics (Shanghai) Ltd
(HTD), on sale and marketing of HTD's products
Read more
BRIEF-Celltrion signs contract worth 53.25 bln won
* Says it signed a 53.25 billion won contract with Celltrion
Healthcare co.,Ltd, to sell antibody drug
Read more
Healthcare co.,Ltd, to sell antibody drug
Read more
BRIEF-AnaptysBio prices IPO of 5 mln shares at $15 per share
* Says initial public offering of 5.00 million common shares
priced at $15.00 per share
Source text for Eikon:
Further company coverage:
Read more
priced at $15.00 per share
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Alamos Gold files for common stock shelf of up to $257.5 mln
* Files for common stock shelf of up to $257.5 million - SEC
filing
Source text: (http://bit.ly/2kunv78)
Further company coverage:
Read more
filing
Source text: (http://bit.ly/2kunv78)
Further company coverage:
Read more
BRIEF-Entellus Medical sees quarterly total rev $21.5 mln - $21.7 mln
* Sees total revenue for quarter-ended december 31, 2016
between $21.5 million - $21.7 million
Read more
between $21.5 million - $21.7 million
Read more
UPDATE 2-U.S. Republican lawmakers tepid over Trump's voter fraud assertions
PHILADELPHIA, Jan 25 (Reuters) - U.S. Republican lawmakers
launched an effort to unify behind a legislative strategy on
Wednesday but showed little appetite to quickly join President
Donald Trump's call for an investigation into what he believes
was large-scale voter fraud in the Nov. 8 election.
Read more
launched an effort to unify behind a legislative strategy on
Wednesday but showed little appetite to quickly join President
Donald Trump's call for an investigation into what he believes
was large-scale voter fraud in the Nov. 8 election.
Read more
UPDATE 2-McKesson's revenue misses as pace of drug price hikes slow
Jan 25 (Reuters) - Drug distributor McKesson Corp's
quarterly revenue missed estimates due to slowing pace of
branded drug price increases amid rising concerns over soaring
prices of medicines.
Read more
quarterly revenue missed estimates due to slowing pace of
branded drug price increases amid rising concerns over soaring
prices of medicines.
Read more
BRIEF-Avinger announces outcomes from pivotal vision study of lumivascular technology
* Avinger announces 24-month outcomes from the pivotal
vision study of lumivascular technology for peripheral artery
disease
Read more
vision study of lumivascular technology for peripheral artery
disease
Read more
U.S. chemical industry body calls for reform of WHO cancer agency
LONDON, Jan 25 (Reuters) - The American Chemistry Council
industry body called on Wednesday for World Health
Organization's cancer agency to reform, accusing it of "dubious
and misleading" work in classifying potential carcinogens.
Read more
industry body called on Wednesday for World Health
Organization's cancer agency to reform, accusing it of "dubious
and misleading" work in classifying potential carcinogens.
Read more
Possible liver injury added to label of Biogen MS drug
Jan 25 (Reuters) - The prescribing label for Biogen Inc's
big-selling oral multiple sclerosis drug Tecfidera has
been updated to include a warning of potential liver injury
that could require hospitalization, the company said on
Wednesday.
Read more
big-selling oral multiple sclerosis drug Tecfidera has
been updated to include a warning of potential liver injury
that could require hospitalization, the company said on
Wednesday.
Read more
BRIEF-Abano Healthcare Group says HY net profit after tax up 73 pct
* HY net profit after tax (NPAT) up 73% to NZ$5.9m ; HY
revenue NZ$116.8m; interim dividend confirmed at 16 cents per
share
Read more
revenue NZ$116.8m; interim dividend confirmed at 16 cents per
share
Read more
AppDynamics deal shows buyouts more lucrative in anemic IPO market
Jan 25 (Reuters) - Cisco Systems Inc's surprise and
costly acquisition of business software firm AppDynamics Inc
just two days ahead of its market debut suggests that U.S. tech
startups are finding more value in buyouts amid a still-tepid
IPO market.
Read more
costly acquisition of business software firm AppDynamics Inc
just two days ahead of its market debut suggests that U.S. tech
startups are finding more value in buyouts amid a still-tepid
IPO market.
Read more
Gene-edited cells keep cancer babies well more than one year on
LONDON, Jan 25 (Reuters) - Two babies rescued from
previously incurable leukaemia after receiving infusions of
gene-edited immune cells are doing well at home more than a year
after initial treatment, scientists said on Wednesday.
Read more
previously incurable leukaemia after receiving infusions of
gene-edited immune cells are doing well at home more than a year
after initial treatment, scientists said on Wednesday.
Read more
General Electric to have logo patch on Boston Celtics jerseys
Jan 25 (Reuters) - The Boston Celtics will wear General
Electric Co's corporate logo on their jerseys during
basketball games beginning next season, the NBA franchise
announced on Wednesday.
Read more
Electric Co's corporate logo on their jerseys during
basketball games beginning next season, the NBA franchise
announced on Wednesday.
Read more
BRIEF-CANCER GENETICS LAUNCHES FOCUSED GENOMIC PANEL FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME
* HAS LAUNCHED A FOCUSED GENOMIC PANEL FOR HEREDITARY BREAST
AND OVARIAN CANCER SYNDROME (HBOC)
Read more
AND OVARIAN CANCER SYNDROME (HBOC)
Read more
INSIGHT-Health insurers quietly shape Obamacare replacement with fewer risks
NEW YORK/WASHINGTON, Jan 25 (Reuters) - U.S. health insurers
are making their case to Republican lawmakers over how Americans
sign up for individual insurance and pushing for other changes
to shape the replacement of former President Barack Obama's
national healthcare law.
Read more
are making their case to Republican lawmakers over how Americans
sign up for individual insurance and pushing for other changes
to shape the replacement of former President Barack Obama's
national healthcare law.
Read more
EU mergers and takeovers (Jan 25)
BRUSSELS, Jan 25 (Reuters) - The following are mergers under
review by the European Commission and a brief guide to the EU
merger process:
Read more
review by the European Commission and a brief guide to the EU
merger process:
Read more
BRIEF-CH2M Hill says Consortium to file arbitration claims against JKC Australia LNG Pty
* Consortium consisting of General Electric Company,
UGL-CH2M JV expects to file arbitration claims against JKC
Australia LNG Pty
Read more
UGL-CH2M JV expects to file arbitration claims against JKC
Australia LNG Pty
Read more
EU clears Abbott acquisition of Alere subject to divestments
BRUSSELS, Jan 25 (Reuters) - European Union antitrust
regulators cleared Abbott Laboratories' proposed $5.8
billion acquisition of diagnostic test maker Alere on
Wednesday, subject to the divestment of some of Alere's
operations.
Read more
regulators cleared Abbott Laboratories' proposed $5.8
billion acquisition of diagnostic test maker Alere on
Wednesday, subject to the divestment of some of Alere's
operations.
Read more
BRIEF-Abbott CEO says is optimistic about the Trump administration: Conf Call
* Abbott says expect challenging conditions in China's
nutrition market to continue in the near term: Conf Call
Read more
nutrition market to continue in the near term: Conf Call
Read more
UPDATE 2-Nutrition unit, strong dollar weigh on Abbott's sales
Jan 25 (Reuters) - Abbott Laboratories reported
quarterly sales just shy of Wall Street expectations, largely
weighed by a strong dollar and waning demand for its nutrition
products, and forecast current-quarter adjusted profit below
estimates.
Read more
quarterly sales just shy of Wall Street expectations, largely
weighed by a strong dollar and waning demand for its nutrition
products, and forecast current-quarter adjusted profit below
estimates.
Read more
BRIEF-Spago: SpagoPix product patent approved in Japan
* Says the Japanese patent authorities has decided to
approve the companys patent application comprising the
nanoparticles that are the foundation of the SpagoPix project
Read more
approve the companys patent application comprising the
nanoparticles that are the foundation of the SpagoPix project
Read more
BRIEF-Abbvie initiates phase 2 clinical trial programs for ABBV-8e12
* Abbvie initiates phase 2 clinical trial programs for
ABBV-8e12, an investigational anti-tau antibody, in early
alzheimer's disease and progressive supranuclear palsy
Source text for Eikon:
Further company coverage:
Read more
ABBV-8e12, an investigational anti-tau antibody, in early
alzheimer's disease and progressive supranuclear palsy
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Positive topline results show Eisai's Lenvatinib meets primary endpoint
* Positive topline results of large phase 3 trial show
Eisai's lenvatinib meets primary endpoint in unresectable
hepatocellular carcinoma
Read more
Eisai's lenvatinib meets primary endpoint in unresectable
hepatocellular carcinoma
Read more
BRIEF-Myovant Sciences initiates phase 3 clinical program of Relugolix
* Myovant Sciences initiates phase 3 clinical program of
Relugolix in women with heavy menstrual bleeding associated with
uterine fibroids
Read more
Relugolix in women with heavy menstrual bleeding associated with
uterine fibroids
Read more
U.S. Republicans to map out strategy for Trump's agenda
WASHINGTON, Jan 25 (Reuters) - U.S. Republican lawmakers
will map out strategy for enacting President Donald Trump's
agenda of repealing and replacing Obamacare and overhauling the
tax code as they gather in Philadelphia on Wednesday for a
three-day policy retreat.
Read more
will map out strategy for enacting President Donald Trump's
agenda of repealing and replacing Obamacare and overhauling the
tax code as they gather in Philadelphia on Wednesday for a
three-day policy retreat.
Read more
Rio Tinto sale to Yancoal resets mood for Australian coal mine deals
SYDNEY, Jan 25 (Reuters) - Chinese-owned Yancoal's
$2.45 billion purchase of the Coal & Allied division of Rio
Tinto is setting the stage for more big-ticket coal
mining acquisitions in Australia, where more than $10 billion in
assets are waiting to be sold.
Read more
$2.45 billion purchase of the Coal & Allied division of Rio
Tinto is setting the stage for more big-ticket coal
mining acquisitions in Australia, where more than $10 billion in
assets are waiting to be sold.
Read more
BRIEF-Shanghai Conant Optics sees FY 2016 net profit up 105.0 pct to 134.3 pct
* Sees FY 2016 net profit to increase by 105.0 percent to
134.3 percent, or to be 105 million yuan to 120 million yuan
Read more
134.3 percent, or to be 105 million yuan to 120 million yuan
Read more
Tuesday, January 24, 2017
BRIEF-Xi'an Qujiang Cultural Tourism sees FY2016 net profit to up by 10 pct to 30 pct
* Sees net profit for FY2016 to increase by 10 percent to 30
percent, compared to net profit of FY2015 (47.9 million yuan)
Read more
percent, compared to net profit of FY2015 (47.9 million yuan)
Read more
Novartis weighs Alcon spinoff, launches share buyback
BASEL, Switzerland, Jan 25 (Reuters) - Novartis AG
may spin off its struggling Alcon eye care business and is
launching a share buyback of up to $5 billion, the Swiss
drugmaker said on Wednesday while reporting fourth-quarter
results that lagged market expectations.
Read more
may spin off its struggling Alcon eye care business and is
launching a share buyback of up to $5 billion, the Swiss
drugmaker said on Wednesday while reporting fourth-quarter
results that lagged market expectations.
Read more
BRIEF-Autobio Diagnostics sees FY2016 net profit to up by 20 pct to 35 pct
* Sees net profit for FY2016 to increase by 20 percent to 35
percent, or to be 334 million yuan to 375 million yuan, compared
to net profit of FY2015 (278 million yuan)
Read more
percent, or to be 334 million yuan to 375 million yuan, compared
to net profit of FY2015 (278 million yuan)
Read more
BRIEF-iNtRON Biotechnology receives patent
* Says it received U.S. patent on Jan. 25, for composition
capable of improving stability of bacteriophage lysin proteins
Read more
capable of improving stability of bacteriophage lysin proteins
Read more
BRIEF-Zhejiang Dian Diagnostics to raise stake in medical instrumentation to 60 percent
* Says co plans to use 36.3 million yuan to buy 16.5 percent
stake in a Shenzhen-based medical instrumentation and will own
60 percent stake in it after transaction
Read more
stake in a Shenzhen-based medical instrumentation and will own
60 percent stake in it after transaction
Read more
BRIEF-Shenzhen Neptunus Bioengineering gets regulatory approval to issue bonds
* Says it gets securities regulator's approval to issue up
to 800 million yuan ($116.69 million) worth of bonds
Read more
to 800 million yuan ($116.69 million) worth of bonds
Read more
Intuitive Surgical sees slower 2017 procedure growth, buys back shares
Jan 24 (Reuters) - Intuitive Surgical Inc on
Tuesday posted fourth-quarter profits that beat Wall Street
expectations, but cautioned that growth in use of its da Vinci
surgical robots will be slower next year due to changes in
hospital trends and competitive factors.
Read more
Tuesday posted fourth-quarter profits that beat Wall Street
expectations, but cautioned that growth in use of its da Vinci
surgical robots will be slower next year due to changes in
hospital trends and competitive factors.
Read more
BRIEF-Genvec says if merger agreement is terminated by either party, it would pay Intrexon a termination fee equal to $550,000
* If merger agreement is terminated by either party, Genvec
must pay Intrexon a termination fee equal to $550,000 - SEC
filing
Source text: (http://bit.ly/2jbIZR1)
Further company coverage:
Read more
must pay Intrexon a termination fee equal to $550,000 - SEC
filing
Source text: (http://bit.ly/2jbIZR1)
Further company coverage:
Read more
UPDATE 2-Trump health nominee says he does not back Medicare privatization
Jan 24 (Reuters) - President Donald Trump's nominee to run
the U.S. Department of Health and Human Services told a
congressional panel on Tuesday that he does not support the
privatization of Medicare and defended his ethics record.
Read more
the U.S. Department of Health and Human Services told a
congressional panel on Tuesday that he does not support the
privatization of Medicare and defended his ethics record.
Read more
Deals of the day-Mergers and acquisitions
Jan 24 (Reuters) - The following bids, mergers, acquisitions
and disposals were reported by 2100 GMT on Tuesday:
Read more
and disposals were reported by 2100 GMT on Tuesday:
Read more
Trump's health nominee says has no plans to privatize Medicare
Jan 24 (Reuters) - President Donald Trump's nominee to run
the U.S. Department of Health and Human Services told a U.S.
congressional panel on Tuesday that he does not support the
privatization of Medicare.
Read more
the U.S. Department of Health and Human Services told a U.S.
congressional panel on Tuesday that he does not support the
privatization of Medicare.
Read more
UPDATE 2-U.S. deficit forecast to shrink in 2017 but climb over next decade
WASHINGTON, Jan 24 (Reuters) - The U.S. budget deficit is
expected to dip during the current fiscal year but balloon over
the next decade, the nonpartisan Congressional Budget Office
said in a report on Tuesday that showed President Donald Trump
inheriting a tricky long-term fiscal picture.
Read more
expected to dip during the current fiscal year but balloon over
the next decade, the nonpartisan Congressional Budget Office
said in a report on Tuesday that showed President Donald Trump
inheriting a tricky long-term fiscal picture.
Read more
BRIEF-Onxeo completes enrollment in phase III study of Livatag for the treatment of hepatocellular carcinoma
* Onxeo completes enrollment in phase III study of Livatag for the treatment of
hepatocellular carcinoma
Read more
hepatocellular carcinoma
Read more
BRIEF-Ose Immunotherapeutics announces IDMC recommends continuation of pivotal Phase 3 clinical trial of Tedopi in non-small cell lung cancer
* Announces that the Independent Data Monitoring Committee (IDMC) recommends continuation of
pivotal Phase 3 clinical trial of Tedopi in non-small cell lung cancer
Read more
pivotal Phase 3 clinical trial of Tedopi in non-small cell lung cancer
Read more
HIGHLIGHTS-The Trump presidency on Jan. 24
U.S. President Donald Trump met with auto executives on Tuesday
and also was expected to give the energy industry a boost with
action on pipelines. Highlights of the day follow:
Read more
and also was expected to give the energy industry a boost with
action on pipelines. Highlights of the day follow:
Read more
BRIEF-Cascadian Therapeutics prices $82.5 mln concurrent offerings of common stock and preferred stock
* Cascadian Therapeutics prices $82.5 million concurrent
offerings of common stock and preferred stock
Read more
offerings of common stock and preferred stock
Read more
BRIEF-Patient Home Monitoring sees Q1 consol EBITDA margin of about 8 pct
* Estimates that its Q1 consolidated EBITDA margin will be
approximately 8 percent
Source text for Eikon:
Further company coverage:
Read more
approximately 8 percent
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Pfenex- reduces size of board- SEC filing
* Pfenex - board reduced size of board to five directors-
sec filing
Source text for Eikon:
Further company coverage:
Read more
sec filing
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Medtronic says first procedure performed in MRI-guided laser ablation trial
* Medtronic PLC says first procedure performed in Medtronic
MRI-guided laser ablation trial to treat common form of epilepsy
Source text for Eikon:
Further company coverage:
Read more
MRI-guided laser ablation trial to treat common form of epilepsy
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Vincent Medical's unit and Inovytec enter into agreement
* Inovytec shall issue and allot to VMIL an aggregate of
12,091 series a preferred shares
Source text for Eikon:
Further company coverage:
Read more
12,091 series a preferred shares
Source text for Eikon:
Further company coverage:
Read more
Monday, January 23, 2017
BRIEF-Lupin Ltd launches generic Ortho-Cyclen 28 tablets in U.S.
* Says Lupin launches generic Ortho-Cyclen 28 tablets in the
US
Source text: http://bit.ly/2j8u2PS
Further company coverage:
Read more
US
Source text: http://bit.ly/2j8u2PS
Further company coverage:
Read more
BRIEF-Kontigo Care signs deal with Stordala Vård och Omsorg
* Initial order value of at least 270,000 Swedish crowns
($30,000) during three year period
Source text for Eikon:
Read more
($30,000) during three year period
Source text for Eikon:
Read more
Swiss stocks - Factors to watch on Jan 24
ZURICH, Jan 24 (Reuters) - Here are some of the main factors
that may affect Swiss stocks on Tuesday:
Read more
that may affect Swiss stocks on Tuesday:
Read more
MIDEAST STOCKS-Gulf may consolidate, Saudi could continue rebound
DUBAI, Jan 24 (Reuters) - Gulf stock markets may consolidate
on Tuesday amid a lack of fresh, positive factors, though Saudi
Arabia could continue a rebound that began on Monday.
Read more
on Tuesday amid a lack of fresh, positive factors, though Saudi
Arabia could continue a rebound that began on Monday.
Read more
BRIEF-Jilin Gpro Titanium Industry to pay 0.3 yuan per 10 shares as 2016 dividend payment
* Says it plans to use undistributed profits to pay cash
dividend of 0.3 yuan per 10 shares (before tax) to the company's
shareholders for 2016
Read more
dividend of 0.3 yuan per 10 shares (before tax) to the company's
shareholders for 2016
Read more
MIDEAST STOCKS - Factors to watch - Jan 24
DUBAI, Jan 24 (Reuters) - Here are some factors that may
affect Middle East stock markets on Tuesday. Reuters has not
verified the press reports and does not vouch for their
accuracy.
Read more
affect Middle East stock markets on Tuesday. Reuters has not
verified the press reports and does not vouch for their
accuracy.
Read more
UPDATE 2-U.S. reaches settlement with Endo on pay-for-delay charges
WASHINGTON, Jan 23 (Reuters) - Endo International Plc
said on Monday it has reached a proposed settlement
with U.S. antitrust regulators under which it will not pay
rivals to delay the introduction of generic competitors to its
medications.
Read more
said on Monday it has reached a proposed settlement
with U.S. antitrust regulators under which it will not pay
rivals to delay the introduction of generic competitors to its
medications.
Read more
UPDATE 3-U.S. blocks health insurer Aetna's $34 bln Humana acquisition
Jan 23 (Reuters) - A U.S. judge blocked on Monday health
insurer Aetna Inc's proposed $34 billion acquisition of
smaller peer Humana Inc, raising the stakes for rival
Anthem Inc as it battles to close a $54 billion deal to
buy Cigna Corp.
Read more
insurer Aetna Inc's proposed $34 billion acquisition of
smaller peer Humana Inc, raising the stakes for rival
Anthem Inc as it battles to close a $54 billion deal to
buy Cigna Corp.
Read more
BRIEF-Medicinova announces positive findings on MN-166 (ibudilast) in alcohol dependence
* Medicinova announces publication of positive findings on
MN-166 (ibudilast) in alcohol dependence
Read more
MN-166 (ibudilast) in alcohol dependence
Read more
BRIEF-Vistagen Therapeutics files for mixed shelf of up to $100 million
* Files for mixed shelf of up to $100 million - SEC filing
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Imprimis Pharmaceuticals files for offering of up to 10.73 mln shares by selling stockholders
* Files for offering of up to aggregate of 10.73 million
shares of co's common stock by the selling stockholders
Source text for Eikon:
Further company coverage:
Read more
shares of co's common stock by the selling stockholders
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Immunogen announces departure of Sandra Poole
* Poole, executive vice president, technical operations and
commercial development, will leave company at end of January
Source text for Eikon:
Further company coverage:
Read more
commercial development, will leave company at end of January
Source text for Eikon:
Further company coverage:
Read more
FTC settles pay-for-delay lawsuit, files two related complaints
WASHINGTON, Jan 23 (Reuters) - The U.S. Federal Trade
Commission said on Monday it had settled allegations that Endo
Pharmaceuticals violated antitrust law when it agreed
to pay rivals Watson Laboratories and Impax to delay introducing
generic versions of two painkillers.
Read more
Commission said on Monday it had settled allegations that Endo
Pharmaceuticals violated antitrust law when it agreed
to pay rivals Watson Laboratories and Impax to delay introducing
generic versions of two painkillers.
Read more
BRIEF-Sera Prognostics files to say it raised about $23 million in equity financing from total offering of $45 million
* Sera Prognostics Inc files to say it raised about $23
million in equity financing from total offering of $45 million -
SEC filing
Source text: (http://bit.ly/2jUygig)
Read more
million in equity financing from total offering of $45 million -
SEC filing
Source text: (http://bit.ly/2jUygig)
Read more
Trump moving U.S. toward era of bilateral trade -White House
WASHINGTON, Jan 23 (Reuters) - President Donald Trump met
with key business leaders on Monday and signed an executive
order withdrawing the United States from the Trans-Pacific
Partnership trade deal, moving the country toward an era of
bilateral trade and job creation at home, the White House said.
Read more
with key business leaders on Monday and signed an executive
order withdrawing the United States from the Trans-Pacific
Partnership trade deal, moving the country toward an era of
bilateral trade and job creation at home, the White House said.
Read more
UPDATE 1-Bangladesh finds two outbreaks of H5N1 bird flu in poultry
PARIS/DHAKA, Jan 23 (Reuters) - Bangladesh discovered two
outbreaks of the highly contagious H5N1 bird flu virus in
poultry last week, according to reports from the World
Organisation for Animal Health (OIE) and a senior Bangladeshi
health ministry official on Monday.
Read more
outbreaks of the highly contagious H5N1 bird flu virus in
poultry last week, according to reports from the World
Organisation for Animal Health (OIE) and a senior Bangladeshi
health ministry official on Monday.
Read more
UPDATE 1-Republican senator: Trump's Obamacare order 'confusing;' replacement law needed
WASHINGTON, Jan 23 (Reuters) - U.S. Republican Senator Susan
Collins called President Donald Trump's executive order against
Obamacare "very confusing" on Monday, saying whatever actions
the Trump administration takes, legislation will still be needed
to replace the health insurance law.
Read more
Collins called President Donald Trump's executive order against
Obamacare "very confusing" on Monday, saying whatever actions
the Trump administration takes, legislation will still be needed
to replace the health insurance law.
Read more
Trump signs order withdrawing U.S. from Trans-Pacific trade deal
WASHINGTON, Jan 23 (Reuters) - President Donald Trump signed
an executive order formally withdrawing the United States from
the 12-nation Trans-Pacific Partnership trade deal on Monday,
following through on a promise from his campaign last year.
Read more
an executive order formally withdrawing the United States from
the 12-nation Trans-Pacific Partnership trade deal on Monday,
following through on a promise from his campaign last year.
Read more
Federal judge blocks Aetna Inc's plan to buy rival Humana
WASHINGTON, Jan 23 (Reuters) - A U.S. federal judge blocked
on Monday health insurer Aetna Inc's proposed $34
billion merger with rival Humana, saying it was illegal under
antitrust law.
Read more
on Monday health insurer Aetna Inc's proposed $34
billion merger with rival Humana, saying it was illegal under
antitrust law.
Read more
BRIEF-Gardner Lewis Asset Management L.P. reports 7.7 pct stake in Derma Sciences - SEC filing
* Gardner Lewis Asset Management, L.P. Reports 7.7 percent
stake in Derma Sciences Inc as of Jan 11, 2017 - SEC filing
Source text: (http://bit.ly/2jQIOyE)
Further company coverage:
(Bengaluru Newsroom: +91 806 749 1136)
Read more
stake in Derma Sciences Inc as of Jan 11, 2017 - SEC filing
Source text: (http://bit.ly/2jQIOyE)
Further company coverage:
(Bengaluru Newsroom: +91 806 749 1136)
Read more
UPDATE 2-Poor countries allowed to import generic drugs - WTO
GENEVA, Jan 23 (Reuters) - Poor countries are allowed to
import generic medicines, World Trade Organization (WTO)
Director General Roberto Azevedo told Reuters on Monday, after
the required two-thirds of members agreed a deal that has taken
more than a decade to finalise.
Read more
import generic medicines, World Trade Organization (WTO)
Director General Roberto Azevedo told Reuters on Monday, after
the required two-thirds of members agreed a deal that has taken
more than a decade to finalise.
Read more
UPDATE 1-Investors gird for impact of Trump healthcare measures
Jan 23 (Reuters) - An order by President Donald Trump that
could scale back enforcement of some Obamacare provisions is
unlikely to sink health insurance stocks, but shares of
hospitals and Medicaid providers could be under pressure over
fears more poor people would lose coverage, analysts said.
Read more
could scale back enforcement of some Obamacare provisions is
unlikely to sink health insurance stocks, but shares of
hospitals and Medicaid providers could be under pressure over
fears more poor people would lose coverage, analysts said.
Read more
BRIEF-Ocular Therapeutix(tm) resubmits NDA for Dextenza(tm)
* Ocular Therapeutix(tm) resubmits NDA for Dextenza(tm) for
the treatment of ocular pain occurring after ophthalmic surgery
Read more
the treatment of ocular pain occurring after ophthalmic surgery
Read more
BRIEF-Wuhan Thalys Medical Technology plans share private placement
* Says it plans to raise up to 1.05 billion yuan ($153.26
million) in private placement of shares to fund projects,
replenish capital
Read more
million) in private placement of shares to fund projects,
replenish capital
Read more
BRIEF-ADMA Biologics to acquire certain assets from Biotest Pharmaceuticals Corp
* ADMA Biologics to acquire certain assets from Biotest
Pharmaceuticals Corporation and become a vertically integrated
commercial plasma products company
Read more
Pharmaceuticals Corporation and become a vertically integrated
commercial plasma products company
Read more
UPDATE 3-Actelion drug setback unlikely to derail J&J talks - analysts
* Shares pare losses after falling more than 1 pct
(Releads, adds analyst reactions, updates shares)
Read more
(Releads, adds analyst reactions, updates shares)
Read more
UPDATE 1-World must not miss early signals of any flu pandemic - WHO
GENEVA, Jan 23 (Reuters) - The World Health Organization
called on all countries to monitor closely outbreaks of deadly
avian influenza in birds and poultry and to report promptly any
human cases that could signal the start of a flu pandemic.
Read more
called on all countries to monitor closely outbreaks of deadly
avian influenza in birds and poultry and to report promptly any
human cases that could signal the start of a flu pandemic.
Read more
UK scientists give cancer risk warning on overdone chips, toast
LONDON, Jan 23 (Reuters) - Potatoes and bread cooked at high
temperatures for a long time could increase the risk of cancer
in people who eat them regularly, British government scientists
said on Monday.
Read more
temperatures for a long time could increase the risk of cancer
in people who eat them regularly, British government scientists
said on Monday.
Read more
BRIEF-Jilin Zixin Pharmaceutical Industrial raises FY 2016 net profit outlook up 301.6 pct to 331.9 pct
* Sees net profit for FY 2016 up 301.6 percent to 331.9
percent, or to be 159 million yuan to 171 million yuan
Read more
percent, or to be 159 million yuan to 171 million yuan
Read more
Sunday, January 22, 2017
BRIEF-Neuron Bio to receive 198,500 euros in product development grant
* To receive 198,500 euros ($213,209) grant for project to develop functional foods from
olives in 2016-2018
Source text: http://bit.ly/2jnTSQw
Read more
olives in 2016-2018
Source text: http://bit.ly/2jnTSQw
Read more
BRIEF-Philips Lighting Q4 profits narrowly miss Reuters poll
* Q4 sales amount to 1,934 million euros ($2.08 billion),
with comparable sales of -3.2 pct (Q4 2015: -2.7 pct) -- Q4
sales 1.98 billion euros in Reuters poll
Read more
with comparable sales of -3.2 pct (Q4 2015: -2.7 pct) -- Q4
sales 1.98 billion euros in Reuters poll
Read more
Actelion study leader says Opsumit missed PAH study endpoint
ZURICH, Jan 23 (Reuters) - Actelion's Opsumit drug
missed a primary endpoint in a study of patients with pulmonary
arterial hypertension due to Eisenmenger Syndrome, a doctor
involved in leading the trial said in a statement issued by the
Swiss drugmaker on Monday.
Read more
missed a primary endpoint in a study of patients with pulmonary
arterial hypertension due to Eisenmenger Syndrome, a doctor
involved in leading the trial said in a statement issued by the
Swiss drugmaker on Monday.
Read more
BRIEF-Inner Mongolia Furui Medical Science sees FY 2016 net profit up 30 pct to 50 pct
* Says it sees 2016 net profit up 30 percent to 50 percent,
from a year ago, as result of increased sales and decreased
costs
Read more
from a year ago, as result of increased sales and decreased
costs
Read more
BRIEF-Zhejiang Dian Diagnostics to buy 43.5 pct stake in medical apparatus and instruments firm for 87 mln yuan
* Says it to acquire 43.5 percent stake in Shenzhen-based
medical apparatus and instruments firm for 87 million yuan
Read more
medical apparatus and instruments firm for 87 million yuan
Read more
BRIEF-Shanghai Kinetic Medical sees FY 2016 net profit up 20 pct to 50 pct
* Says it sees 2016 net profit up 20 percent to 50 percent,
from a year ago, as result of increased sales and company
acquisition
Read more
from a year ago, as result of increased sales and company
acquisition
Read more
BRIEF-Shandong Buchang Pharma sees 2016 net profit down about 55 pct
* Says it sees 2016 net profit down about 55 pct y/y versus
3.5 billion yuan ($509.25 million) year ago
Read more
3.5 billion yuan ($509.25 million) year ago
Read more
BRIEF-Hunan Hansen Pharma's controlling shareholder unloads stake in the company
* Says its controlling shareholder has sold 4.84 pct stake
in the company on Jan 20, taking its holdings to 47.12 pct after
transaction
Read more
in the company on Jan 20, taking its holdings to 47.12 pct after
transaction
Read more
BRIEF-Regeneus receives upfront payment of US$5.5 mln from AGC
* Is expected to receive a further US$11 mln in specific
development and approval milestone payments
Read more
development and approval milestone payments
Read more
BRIEF-Airxpanders Inc seeks trading halt
* Seeks trading halt pending announcement by airxpanders in
relation to a proposed capital raising
Source text for Eikon:
Further company coverage:
Read more
relation to a proposed capital raising
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Lepu Medical Technology sees 2016 net profit up 30-40 pct
* Says it sees 2016 net profit up 30-40 percent from 520.9
million yuan ($75.79 million) a year ago
Read more
million yuan ($75.79 million) a year ago
Read more
BRIEF-Comvita expects reported after-tax loss of NZ$7-7.5 mln for HY
* Likely to see a 60% shortfall in harvest expectations this
season from our own apiary operations
Read more
season from our own apiary operations
Read more
BRIEF-Dimerix Ltd seeks trading halt
* Seeks trading halt pending announcement of a capital
raising
Source text for Eikon:
Further company coverage:
Read more
raising
Source text for Eikon:
Further company coverage:
Read more
UPDATE 1-Trump may not enforce individual health insurance mandate--aide
WASHINGTON, Jan 22 (Reuters) - The Trump administration may
no longer enforce a rule requiring individual Americans to carry
health insurance or pay a penalty if they do not, a senior White
House official said on Sunday
Read more
no longer enforce a rule requiring individual Americans to carry
health insurance or pay a penalty if they do not, a senior White
House official said on Sunday
Read more
Egypt's military to enter pharmaceutical industry
CAIRO, Jan 22 (Reuters) - Egypt's military has received the
licence required to form a pharmaceutical company, a decree by
Prime Minister Sherif Ismail published on Sunday showed.
Read more
licence required to form a pharmaceutical company, a decree by
Prime Minister Sherif Ismail published on Sunday showed.
Read more
Americans won't lose coverage in health law reform - Trump aide
WASHINGTON, Jan 22 (Reuters) - The Trump administration will
not allow 20 million people who rely on the Affordable Care Act
for their health insurance to go without coverage when the law,
known as Obamacare, is repealed and replaced with a new plan, a
senior White House official said on Sunday.
Read more
not allow 20 million people who rely on the Affordable Care Act
for their health insurance to go without coverage when the law,
known as Obamacare, is repealed and replaced with a new plan, a
senior White House official said on Sunday.
Read more
Saturday, January 21, 2017
Former U.S. President George H.W. Bush's health improves
NEW YORK, Jan 21 (Reuters) - Former U.S. President George
H.W. Bush is recovering well from pneumonia but will remain in
the intensive care unit at the Texas hospital where he has spent
the last week, a spokesman said in a statement.
Read more
H.W. Bush is recovering well from pneumonia but will remain in
the intensive care unit at the Texas hospital where he has spent
the last week, a spokesman said in a statement.
Read more
UPDATE 2-Trump, in Oval Office, signs first order on Obamacare
WASHINGTON, Jan 20 (Reuters) - President Donald Trump
directed government agencies on Friday to freeze regulations and
take steps to weaken Obamacare, using his first hours in the
White House to make good on a campaign promise to start
dismantling his predecessor's healthcare law.
Read more
directed government agencies on Friday to freeze regulations and
take steps to weaken Obamacare, using his first hours in the
White House to make good on a campaign promise to start
dismantling his predecessor's healthcare law.
Read more
Friday, January 20, 2017
CORRECTED-UPDATE 1-Trump, in Oval Office, signs first order on Obamacare
WASHINGTON, Jan 20 (Reuters) - President Donald Trump signed
his first executive order on Friday, heading into the Oval
Office shortly after his inaugural parade to direct agencies to
ease regulations associated with Obamacare, the signature
healthcare law of his predecessor that Trump has vowed to
replace.
Read more
his first executive order on Friday, heading into the Oval
Office shortly after his inaugural parade to direct agencies to
ease regulations associated with Obamacare, the signature
healthcare law of his predecessor that Trump has vowed to
replace.
Read more
Trump, in Oval Office, signs first executive order on Obamacare
WASHINGTON, Jan 20 (Reuters) - President Donald Trump signed
his first executive order on Friday in the Oval Office shortly
after his inaugural parade ended, directing agencies to ease the
regulatory burdens associated with Obamacare as the U.S.
Congress determines how to repeal and replace the health care
law.
Read more
his first executive order on Friday in the Oval Office shortly
after his inaugural parade ended, directing agencies to ease the
regulatory burdens associated with Obamacare as the U.S.
Congress determines how to repeal and replace the health care
law.
Read more
BRIEF-Resmed and BMC/3B Medical settle global litigation
* Resmed Inc - Settlement did not include an admission of
liability or wrongdoing by any party
Read more
liability or wrongdoing by any party
Read more
UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit
Jan 20 (Reuters) - Merck & Co said it agreed to
enter into a settlement and license agreement with Bristol-Myers
Squibb Co and Ono Pharmaceutical Co Ltd to
resolve all global patent-infringement litigation related to its
cancer drug, Keytruda.
Read more
enter into a settlement and license agreement with Bristol-Myers
Squibb Co and Ono Pharmaceutical Co Ltd to
resolve all global patent-infringement litigation related to its
cancer drug, Keytruda.
Read more
BRIEF-Bioptix enters agreement with certain shareholders providing for termination of certain pending litigation
* On Jan 18, entered agreement with certain shareholders
providing for termination of certain pending litigation - SEC
filing
Read more
providing for termination of certain pending litigation - SEC
filing
Read more
Merck, Bristol-Myers agree to settle Keytruda patent suit
Jan 20 (Reuters) - Merck & Co said it agreed to
enter into a settlement and license agreement with Bristol-Myers
Squibb Co and Ono Pharmaceutical Co Ltd to
resolve a patent litigation related to its cancer drug,
Keytruda.
Read more
enter into a settlement and license agreement with Bristol-Myers
Squibb Co and Ono Pharmaceutical Co Ltd to
resolve a patent litigation related to its cancer drug,
Keytruda.
Read more
BRIEF-Orbimed Advisors Llc reports 18.8 pct stake in Viewray Inc
* Orbimed Advisors Llc reports 18.8 percent stake in Viewray
Inc as of January 18, 2017 versus 22.6 percent stake as of
August 22, 2016 - SEC filing
Source text: [http://bit.ly/2kbwQkd]
Further company coverage:
Read more
Inc as of January 18, 2017 versus 22.6 percent stake as of
August 22, 2016 - SEC filing
Source text: [http://bit.ly/2kbwQkd]
Further company coverage:
Read more
BRIEF-Cesca Therapeutics files for resale of up to 950,000 common shares
* Files for resale of up to 950,000 shares of co's common
stock by the selling stockholders - sec filing
Read more
stock by the selling stockholders - sec filing
Read more
BRIEF-Ovid Therapeutics files to say it raised about $25.9 mln in equity financing
* Ovid Therapeutics Inc files to say it raised about $25.9
million in equity financing - SEC filing
Source text: (http://bit.ly/2iTAbPH)
Read more
million in equity financing - SEC filing
Source text: (http://bit.ly/2iTAbPH)
Read more
UPDATE 2-Former President George H.W. Bush watched inaugural from hospital room
AUSTIN, Texas, Jan 20 (Reuters) - Former U.S. President
George H.W. Bush, who has spent nearly a week at a Houston
hospital where he is being treated for pneumonia, watched the
inauguration of President Donald Trump from the intensive care
unit, a family spokesman said.
Read more
George H.W. Bush, who has spent nearly a week at a Houston
hospital where he is being treated for pneumonia, watched the
inauguration of President Donald Trump from the intensive care
unit, a family spokesman said.
Read more
France to review food whitener additive for health risks
PARIS, Jan 20 (Reuters) - The French government has ordered
a review of the safety of titanium dioxide as a food additive
after a scientific study released on Friday found health effects
in animals that consumed the substance.
Read more
a review of the safety of titanium dioxide as a food additive
after a scientific study released on Friday found health effects
in animals that consumed the substance.
Read more
BRIEF-Sabby Management reports 6.81 pct passive stake in Sunshine Heart
* Sabby Management LLC reports 6.81 pct passive stake in
Sunshine Heart Inc as of Jan 19 - SEC filing
Source text: (http://bit.ly/2jVb54C)
Further company coverage:
Read more
Sunshine Heart Inc as of Jan 19 - SEC filing
Source text: (http://bit.ly/2jVb54C)
Further company coverage:
Read more
BRIEF-Baillie Gifford & Co reports 7.25% passive stake in Dexcom Inc as of Dec 31, 2016
* Reports 7.25 percent passive stake in Dexcom Inc as of 31
December 2016 - SEC filing
Source text (http://bit.ly/2jwYmFB)
Further company coverage:
Read more
December 2016 - SEC filing
Source text (http://bit.ly/2jwYmFB)
Further company coverage:
Read more
BRIEF-Cytosorbents launches VetResQ for U.S. veterinary market
* Cytosorbents launches VetResQ for U.S. veterinary market
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Voyager Therapeutics announces updates from phase 1B trial of VY-AADC01
* Voyager Therapeutics announces updates from phase 1b trial
of vy-aadc01 for advanced parkinson's disease
Read more
of vy-aadc01 for advanced parkinson's disease
Read more
BRIEF-Life Healthcare Group to raise 9 bln rand through rights offering
* Update on proposed rights offer and modifications to
resolutions contained in the notice of annual general meeting
Read more
resolutions contained in the notice of annual general meeting
Read more
UPDATE 1-GE profit up 36 percent, sales slow; affirms 2017 forecast
Jan 20 (Reuters) - General Electric Co reported a
35.7 percent jump in quarterly profit on Friday, helped by
strength in its power and renewable energy businesses, and
affirmed its growth and profit forecasts for 2017.
Read more
35.7 percent jump in quarterly profit on Friday, helped by
strength in its power and renewable energy businesses, and
affirmed its growth and profit forecasts for 2017.
Read more
BRIEF-Pluristem increases previously announced bought deal offering of common stock and warrants to $15,000,000
* Pluristem increases previously announced bought deal
offering of common stock and warrants to $15,000,000
Source text for Eikon:
Further company coverage:
Read more
offering of common stock and warrants to $15,000,000
Source text for Eikon:
Further company coverage:
Read more
BRIEF-General Electric Co Q4 results press release
Please click on the link below for General Electric Co's Q4
earnings press release:
Source text:
http://invent.ge/2k7RuNJ
Read more
earnings press release:
Source text:
http://invent.ge/2k7RuNJ
Read more
BRIEF-General Electric Co Q4 results presentation
Please click on the link below for General Electric Co's Q4
earnings presentation:
Source text:
(http://invent.ge/2jTTH0h)
Read more
earnings presentation:
Source text:
(http://invent.ge/2jTTH0h)
Read more
BRIEF-Rici Healthcare Holdings says Cai Di appointed vice president
* Lin Hefei was appointed as a vice president of company
Source text for Eikon:
Further company coverage:
Read more
Source text for Eikon:
Further company coverage:
Read more
BRIEF-B-Soft announces shareholding structure changes
* Says its shareholder Youngor lowers stake in
co to 5.70 percent from 11.39 percent, after sale of co's shares
to co's general manager Zhang Luzheng
Read more
co to 5.70 percent from 11.39 percent, after sale of co's shares
to co's general manager Zhang Luzheng
Read more
BRIEF-China Meheco expects 2016 net profit to rise 48-58 pct
* Says it expects 2016 net profit to rise 48-58 percent y/y
versus net profit of 614.46 million yuan ($89.39 million) year
ago
Read more
versus net profit of 614.46 million yuan ($89.39 million) year
ago
Read more
BRIEF-Asymchem Laboratories Tianjin sees FY 2016 net profit up 50 pct to 70 pct
* Sees net profit for FY 2016 up 50 percent to 70 percent,
or to be 230.3 million yuan to 261 million yuan
Read more
or to be 230.3 million yuan to 261 million yuan
Read more
Thursday, January 19, 2017
BRIEF-Shanghai Kaibao Pharmaceutical sees FY 2016 net profit down 0 pct to 8 pct
* Sees net profit for FY 2016 down 0 percent to 8 percent,
or to be 259.1 million yuan to 281.6 million yuan
Read more
or to be 259.1 million yuan to 281.6 million yuan
Read more
Swiss stocks - Factors to watch on Jan 20
ZURICH, Jan 20 (Reuters) - Here are some of the main factors
that may affect Swiss stocks on Friday:
Read more
that may affect Swiss stocks on Friday:
Read more
BRIEF-Amplitude surgical authorised to market Anatomic total knee prosthesis in U.S.
* Announces authorisation to commercialize in U.S. its
anatomic total knee prosthesis
Source text: http://bit.ly/2jFz6iB
Further company coverage:
(Gdynia Newsroom:)
Read more
anatomic total knee prosthesis
Source text: http://bit.ly/2jFz6iB
Further company coverage:
(Gdynia Newsroom:)
Read more
U.S. governors want Congress to keep funding health benefits for poor
WASHINGTON, Jan 19 (Reuters) - U.S. Republican governors on
Thursday urged Washington lawmakers to keep funding health
benefits for millions of low-income Americans, even as Congress
is working to repeal Obamacare, President Barack Obama's
landmark health insurance law.
Read more
Thursday urged Washington lawmakers to keep funding health
benefits for millions of low-income Americans, even as Congress
is working to repeal Obamacare, President Barack Obama's
landmark health insurance law.
Read more
PRESS DIGEST- British Business - Jan 20
Jan 20 (Reuters) - The following are the top stories on the
business pages of British newspapers. Reuters has not verified
these stories and does not vouch for their accuracy.
Read more
business pages of British newspapers. Reuters has not verified
these stories and does not vouch for their accuracy.
Read more
Bristol-Myers won't seek accelerated Opdivo lung cancer approval
Jan 19 (Reuters) - Bristol-Myers Squibb Co on
Thursday said it has decided not to seek accelerated U.S.
approval for its combination of two immunotherapy drugs as an
initial treatment for lung cancer.
Read more
Thursday said it has decided not to seek accelerated U.S.
approval for its combination of two immunotherapy drugs as an
initial treatment for lung cancer.
Read more
UPDATE 1-U.S. health agency tells Grassley there is no EpiPen deal yet
NEW YORK, Jan 19 (Reuters) - Mylan NV has yet to
reach a settlement with the U.S. Department of Justice over the
classification in the Medicaid program of its life-saving EpiPen
allergy treatment, according to a letter from a regulatory
agency disclosed on Thursday.
Read more
reach a settlement with the U.S. Department of Justice over the
classification in the Medicaid program of its life-saving EpiPen
allergy treatment, according to a letter from a regulatory
agency disclosed on Thursday.
Read more
UPDATE 1-U.S. judge delays Texas plan to cut Planned Parenthood funding
AUSTIN, Texas, Jan 19 (Reuters) - A U.S. judge issued a
temporary restraining on Thursday halting Texas' plan to cut
Medicaid funding for Planned Parenthood to give him more time to
consider thousands of pages of documents filed in the
politically charged case, court records showed.
Read more
temporary restraining on Thursday halting Texas' plan to cut
Medicaid funding for Planned Parenthood to give him more time to
consider thousands of pages of documents filed in the
politically charged case, court records showed.
Read more
Investors pull $3 bln from U.S.-based stock funds in week -Lipper
NEW YORK, Jan 19 (Reuters) - Investors pulled $3.1 billion
from U.S.-based stock funds over the past week, following three
straight weeks of pouring cash into those investments, Lipper
data showed on Thursday.
Read more
from U.S.-based stock funds over the past week, following three
straight weeks of pouring cash into those investments, Lipper
data showed on Thursday.
Read more
UPDATE 1-Synergy wins U.S. approval for constipation drug
Jan 19 (Reuters) - The U.S. Food and Drug Administration
said on Thursday it had approved Synergy Pharmaceuticals Inc's
drug to treat chronic idiopathic constipation (CIC).
Read more
said on Thursday it had approved Synergy Pharmaceuticals Inc's
drug to treat chronic idiopathic constipation (CIC).
Read more
BRIEF-FDA approves Trulance for chronic idiopathic constipation
* FDA- Trulance is manufactured by New York, New York-based
Synergy Pharmaceuticals Inc
Source text for Eikon:
Further company coverage:
Read more
Synergy Pharmaceuticals Inc
Source text for Eikon:
Further company coverage:
Read more
U.S. top court to hear Bristol-Myers out-of-state injury appeal
Jan 19 (Reuters) - The U.S. Supreme Court on Thursday agreed
to hear an appeal by pharmaceutical company Bristol-Myers Squibb
Co in a dispute involving its blood-thinning medication
Plavix that could limit where corporations can be sued, the
second such case it has taken up in the past week.
Read more
to hear an appeal by pharmaceutical company Bristol-Myers Squibb
Co in a dispute involving its blood-thinning medication
Plavix that could limit where corporations can be sued, the
second such case it has taken up in the past week.
Read more
Deals of the Day-Mergers and acquisitions
Jan 19 (Reuters) - The following bids, mergers, acquisitions
and disposals were reported by 2000 GMT on Thursday:
Read more
and disposals were reported by 2000 GMT on Thursday:
Read more
UPDATE 1-Costco to pay $11.75 mln over lax U.S. pharmacy controls
Jan 19 (Reuters) - Costco Wholesale Corp will pay
$11.75 million to resolve claims that some of its pharmacies
filled improper or incomplete prescriptions for controlled
substances in violation of federal regulations, the U.S. Justice
Department said on Thursday.
Read more
$11.75 million to resolve claims that some of its pharmacies
filled improper or incomplete prescriptions for controlled
substances in violation of federal regulations, the U.S. Justice
Department said on Thursday.
Read more
BRIEF-Adynxx says has raised about $16 mln in equity financing - SEC filing
* Adynxx Inc says it has raised about $16 million in equity
financing from total offering amount of about $16 million - SEC
filing
Source text: (http://bit.ly/2iGsQrm)
Read more
financing from total offering amount of about $16 million - SEC
filing
Source text: (http://bit.ly/2iGsQrm)
Read more
BRIEF-Rhoen Klinikum says plans to appoint Stephan Holzinger as new CEO
* dgap-adhoc: rhön-klinikum ag: decision making process of
supervisory board of rhön- klinikum concerning reorganization
of management board
Read more
supervisory board of rhön- klinikum concerning reorganization
of management board
Read more
UPDATE 2-Ex-president George H.W. Bush had good night's rest, remains in ICU
AUSTIN, Texas, Jan 19 (Reuters) - Former U.S. president
George H.W. Bush remains in stable condition with pneumonia in
the intensive care unit of a Houston hospital and his wife,
Barbara Bush, is making progress for treatment of bronchitis at
the same hospital, a spokesman said on Thursday.
Read more
George H.W. Bush remains in stable condition with pneumonia in
the intensive care unit of a Houston hospital and his wife,
Barbara Bush, is making progress for treatment of bronchitis at
the same hospital, a spokesman said on Thursday.
Read more
BRIEF-UCB files Briviact CV in US as monotherapy treatment for adult epilepsy patients with partial-onset seizures
* UCB files Briviact (brivaracetam) CV in the US as
monotherapy treatment for adult epilepsy patients with
partial-onset seizures
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
monotherapy treatment for adult epilepsy patients with
partial-onset seizures
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
BRIEF-Roche Holding AG says Troponin T test cleared by FDA
* has received 510(k) clearance for its elecsys Troponin T
Gen 5 STAT blood test for patients with a suspected heart attack
Source text for Eikon:
Further company coverage:
Read more
Gen 5 STAT blood test for patients with a suspected heart attack
Source text for Eikon:
Further company coverage:
Read more
French foie gras farmers angry as bird flu grips region
NOGARO, France, Jan 19 (Reuters) - The mood among the 300
foie gras producers packed into a town hall in southwest France
last week was far from festive, having been forced into a huge
cull of birds caused by a second bird flu outbreak in as many
years at a loss of millions of euros.
Read more
foie gras producers packed into a town hall in southwest France
last week was far from festive, having been forced into a huge
cull of birds caused by a second bird flu outbreak in as many
years at a loss of millions of euros.
Read more
LVMH to take up to 10 pct of Italy's eyewear firm Marcolin - source
MILAN, Jan 19 (Reuters) - French luxury goods group LVMH
is set to take a stake of up to 10 percent in unlisted
Italian eyewear maker Marcolin as it seeks to strengthen control
over manufacturing of its spectacles, a source close to the
matter said on Thursday.
Read more
is set to take a stake of up to 10 percent in unlisted
Italian eyewear maker Marcolin as it seeks to strengthen control
over manufacturing of its spectacles, a source close to the
matter said on Thursday.
Read more
As more Latin Americans eat processed food, obesity rates surge
SANTIAGO, Jan 19 (Reuters) - Latin America, once plagued by
malnutrition, now faces a different type of public health crisis
as processed food increasingly replaces traditionally prepared
dishes, leading to a surge in obesity rates, a United Nations
report showed on Thursday.
Read more
malnutrition, now faces a different type of public health crisis
as processed food increasingly replaces traditionally prepared
dishes, leading to a surge in obesity rates, a United Nations
report showed on Thursday.
Read more
Sweating in sauna might help keep brain healthy -Finnish study
HELSINKI, Jan 18 (Reuters) - Regular visits to the sauna can
help lower the risk of developing dementia and Alzheimer's
disease as well as dying of heart ailments, a Finnish study
suggests.
Read more
help lower the risk of developing dementia and Alzheimer's
disease as well as dying of heart ailments, a Finnish study
suggests.
Read more
BRIEF-Baxter's renal therapy services significantly reduced peritonitis infections among home dialysis patients
* Baxter's renal therapy services significantly reduced
peritonitis infections among home dialysis patients
Read more
peritonitis infections among home dialysis patients
Read more
BRIEF-Adamis Pharmaceuticals announces FDA acceptance of its Epinephrine Pre-filled Syringe
* Adamis Pharmaceuticals announces FDA acceptance of
resubmission of its Epinephrine pre-filled syringe NDA
Source text for Eikon:
Further company coverage:
Read more
resubmission of its Epinephrine pre-filled syringe NDA
Source text for Eikon:
Further company coverage:
Read more
BRIEF-Allergan announces FDA approval of RHOFADE cream
* Allergan announces FDA approval of RHOFADE (oxymetazoline
hydrochloride) cream, 1% for the topical treatment of persistent
facial Erythema associated with Rosacea in adults
Read more
hydrochloride) cream, 1% for the topical treatment of persistent
facial Erythema associated with Rosacea in adults
Read more
BRIEF-TapImmune files to register for resale about 2.7 mln shares of co's common stock
* TapImmune Inc files to register for resale about 2.7
million shares of co's common stock currently held by the
selling stockholders - sec filing
Read more
million shares of co's common stock currently held by the
selling stockholders - sec filing
Read more
BRIEF-Pharmathene & Altimmune announces merger
* Pharmathene and Altimmune announce merger to create
immunotherapeutics company targeting infectious diseases
Read more
immunotherapeutics company targeting infectious diseases
Read more
BRIEF-Cytori to acquire proprietary nanoparticle development platform
* Cytori to acquire proprietary nanoparticle development
platform to enhance regenerative medicine leadership position
Read more
platform to enhance regenerative medicine leadership position
Read more
FEATURE-Women marching against Trump plan next step: public office
NEW YORK, Jan 19 (Reuters) - After she spends Saturday
marching in Washington among an expected 200,000 women
protesting the presidency of Donald Trump on his first full day
in office, Amy Davis-Comstock plans to take her first steps
toward her own possible run for office.
Read more
marching in Washington among an expected 200,000 women
protesting the presidency of Donald Trump on his first full day
in office, Amy Davis-Comstock plans to take her first steps
toward her own possible run for office.
Read more
BRIEF-Rhoen Klinikum: significant structural burdens on FY 2017 results
* Management board expects since today significant structural burdens on results in a range
of low to middle two digit millions for current financial year 2017
Read more
of low to middle two digit millions for current financial year 2017
Read more
BRIEF-Guangdong Biolight Meditech expects FY 2016 net profit to increase by 180 to 209.98 pct
* Says net profit of FY 2016 expected to increase by 180
percent to 209.98 percent, or to be 66.97 million to 74.14
million yuan
Read more
percent to 209.98 percent, or to be 66.97 million to 74.14
million yuan
Read more
BRIEF-Ramkhamhaeng Hospital announces acquisition of investment in Vibharam Hospital
* Board of directors have new agreement that co will
purchase new shares of Vibharam Hospital in amount of 4.1
million shares at 14 Baht per share
Read more
purchase new shares of Vibharam Hospital in amount of 4.1
million shares at 14 Baht per share
Read more
BRIEF-Guangdong Biolight Meditech unit to jointly set up hospital
* Says its subsidiary will use 6.5 million yuan to jointly
set up a hospital in Xiantao with an individual
Read more
set up a hospital in Xiantao with an individual
Read more
BRIEF-Pharma Research Products signs contract worth 13.29 bln won
* Says it signed a 13.29 billion won exclusive contract with
CNP to export cosmetic "D+CELL" in China
Read more
CNP to export cosmetic "D+CELL" in China
Read more
BRIEF-Pharmaids Pharmacuticals says agreement with Unifranco Life Sciences for sale of assets
* Entered into agreement with Unifranco Life Sciences for
sale of assets at Kondamadugu, Telangana
Source text: (http://bit.ly/2jBO3SH)
Further company coverage:
Read more
sale of assets at Kondamadugu, Telangana
Source text: (http://bit.ly/2jBO3SH)
Further company coverage:
Read more
BRIEF-Lanhai Medical Investment retires 4.2 mln treasury stock shares
* Says it retired its 4.2 million shares which were
repurchased from the public, representing a 0.5 percent stake of
its total stock issue, on Jan. 19
Read more
repurchased from the public, representing a 0.5 percent stake of
its total stock issue, on Jan. 19
Read more
Wednesday, January 18, 2017
GSK grabs Astra executive to replace exiting pharma head
LONDON, Jan 19 (Reuters) - GlaxoSmithKline said on
Thursday that Abbas Hussain, its global head of pharmaceuticals,
is leaving the company and will be replaced by Luke Miels from
AstraZeneca.
Read more
Thursday that Abbas Hussain, its global head of pharmaceuticals,
is leaving the company and will be replaced by Luke Miels from
AstraZeneca.
Read more
BRIEF-Richter, Allergan sign distribution supply agreement for Levosert
* Richter, Allergan sign distribution supply agreement to
sell a female medical product in europe - statement
Read more
sell a female medical product in europe - statement
Read more
BRIEF-Biomerieux 2016 sales up at 2,103 million euros
* Remarkable growth in sales in 2016, up 9.6 pct like-for-like, lifted by all regions and
all strategic lines
Read more
all strategic lines
Read more
BRIEF-Nanjing Hicin Pharmaceutical sees FY 2016 net profit up 10 pct to 20 pct
* Sees net profit for FY 2016 to increase by 10 percent to
20 percent, or to be 44.4 million yuan to 48.4 million yuan
Read more
20 percent, or to be 44.4 million yuan to 48.4 million yuan
Read more
BRIEF-Intron Biotechnology receives patent
* Says it receives patent about composition effective for
improving the stability of bacteriophage lysin proteins
Read more
improving the stability of bacteriophage lysin proteins
Read more
BRIEF-Dezhan Health sees FY 2016 net profit up 10,458 pct to 11,183 pct
* Sees net profit for FY 2016 up 10,458 percent to 11,183
percent, or to be 650.3 million yuan to 695 million yuan
Read more
percent, or to be 650.3 million yuan to 695 million yuan
Read more
BRIEF-Abano Healthcare Group warns of solicitation calls in regards to offer
* Aware that an australian solicitation call centre has been
hired by healthcare partners, to contact abano shareholders
Read more
hired by healthcare partners, to contact abano shareholders
Read more
Fitch: Agency Less Optimistic than Market on Top Indian Companies
(The following statement was released by the rating agency)
Link to Fitch Ratings' Report: 100 Indian Listed Corporates:
Credit Change Zones
2016
https://www.fitchratings.com/site/re/890602
SYDNEY/NEW DELHI/SINGAPORE, January 18 (Fitch) Fitch Ratings and
India Ratings &
Research (collectively "Fitch") are less optimistic in their
projections for the
27 Indian corporates they publicly rate compared with Bloomberg
consensus
estimates (BEst), the agency says in its credit change zone
report for
Read more
Link to Fitch Ratings' Report: 100 Indian Listed Corporates:
Credit Change Zones
2016
https://www.fitchratings.com/site/re/890602
SYDNEY/NEW DELHI/SINGAPORE, January 18 (Fitch) Fitch Ratings and
India Ratings &
Research (collectively "Fitch") are less optimistic in their
projections for the
27 Indian corporates they publicly rate compared with Bloomberg
consensus
estimates (BEst), the agency says in its credit change zone
report for
Read more
BRIEF-Richard Uihlein reports 7.89 pct stake in Galectin Therapeutics
* Richard Uihlein reports 7.89 percent stake in Galectin
Therapeutics Inc as of Dec 22 - SEC filing
Source text: (http://bit.ly/2jMCBRA)
Further company coverage:
Read more
Therapeutics Inc as of Dec 22 - SEC filing
Source text: (http://bit.ly/2jMCBRA)
Further company coverage:
Read more
Subscribe to:
Posts (Atom)